var title_f18_13_18640="Figure 8 bandage";
var content_f18_13_18640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Figure of eight bandage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 166px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure of eight bandage with shoulders in position of attention.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eiff, MP, Hatch, RL, Calmbach, W (Eds). Fracture Management for Primary Care, 2nd Edition, W.B. Saunders Company, Philadelphia 2002. Illustration used with permission of Elsevier Inc. All right reserved. Copyright &copy;2002 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18640=[""].join("\n");
var outline_f18_13_18640=null;
var title_f18_13_18641="ECG grid";
var content_f18_13_18641=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Grid lines and standardization of the ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 318px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The electrocardiogam is recorded on paper that has large boxes (heavy lines) of 0.5 cm sides. On the horizontal axis, each large box, which represents 0.2 seconds at a typical paper speed of 25mm/sec, is divided into five smaller boxes, each one representing 0.04 seconds. On the vertical axis, the large box also has five subdivisions, each 1 mm in height; 10 mm equals 1 mV with standard calibration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18641=[""].join("\n");
var outline_f18_13_18641=null;
var title_f18_13_18642="Vitamin B5 (pantothenic acid): Drug information";
var content_f18_13_18642=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vitamin B5 (pantothenic acid): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/21/38227?source=see_link\">",
"    see \"Vitamin B5 (pantothenic acid): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3034075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Panto-250 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F206315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vitamin, Water Soluble",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Adequate intake (AI) (IOM, 1998):",
"     </b>",
"     Oral: 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pregnancy: 6 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lactation: 7 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13930926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Adequate intake (AI) (IOM, 1998):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1-6 months: 1.7 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     7-12 months: 1.8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1-3 years: 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     4-8 years: 3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     9-13 years: 4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;14 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Panto-250: 250 mg [contains calcium 23 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 200 mg/5 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 100 mg, 200 mg, 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary supplement",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13930918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13930919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pantothenic acid is found in breast milk; concentrations may be increased by use of maternal supplements (IOM, 1998)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pantothenic Acid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $2.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (90): $10.59",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calcium Pantothenicum (PL);",
"     </li>",
"     <li>",
"      Kerato Biciron (DE);",
"     </li>",
"     <li>",
"      Pantothen Streuli (CH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13930920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pantothenic acid is required for the synthesis and maintenance of coenzyme A.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13930922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Absorbed in the intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hydrolyzed in the intestine to coenzyme A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      </i>",
"      <sub>",
"       6",
"      </sub>",
"      <i>",
"       , Folate, Vitamin B",
"      </i>",
"      <sub>",
"       12",
"      </sub>",
"      <i>",
"       , Pantothenic Acid, Biotin and Choline",
"      </i>",
"      , Washington, DC: National Academy Press, 1998.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10191 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18642=[""].join("\n");
var outline_f18_13_18642=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3034075\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206315\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206311\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930926\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206312\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206306\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206299\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206307\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299818\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222132\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930918\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930919\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323616\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206309\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930920\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930922\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10191\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10191|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/21/38227?source=related_link\">",
"      Vitamin B5 (pantothenic acid): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_13_18643="Sulfacetamide (ophthalmic): Pediatric drug information";
var content_f18_13_18643=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"17\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sulfacetamide (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/61/32723?source=see_link\">",
"    see \"Sulfacetamide (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/55/18292?source=see_link\">",
"    see \"Sulfacetamide (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9523096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bleph&reg;-10;",
"     </li>",
"     <li>",
"      Sulfamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9523097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AK Sulf Liq;",
"     </li>",
"     <li>",
"      Bleph 10 DPS;",
"     </li>",
"     <li>",
"      Diosulf&trade;;",
"     </li>",
"     <li>",
"      PMS-Sulfacetamide;",
"     </li>",
"     <li>",
"      Sodium Sulamyd",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10527189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Sulfonamide Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10527199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/61/32723?source=see_link\">",
"      see \"Sulfacetamide (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;2 months and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Apply to lower conjunctival sac 1-4 times/day and at bedtime or apply 1/2\" to 1\" into the conjunctival sac at night in conjunction with the use of drops during the day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution: Instill 1-2 drops into the lower conjunctival sac every 1-3 hours according to severity of infection during the waking hours and less frequently at night; increase dosing interval as condition responds. Usual duration of treatment: 7-10 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9523211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic, as sodium: 10% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]: 10% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bleph&reg;-10: 10% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sulfamide: 10% (15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9523099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10527200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact of tube or bottle tip with skin or eye. Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10527196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; discolored or cloudy solutions should not be used; sulfacetamide is inactivated by blood or purulent exudates",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10527190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prophylaxis of conjunctivitis, corneal ulcers, and other superficial ocular infections due to susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9523083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bleph&reg;-10 may be confused with Blephamide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9523149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular (following ophthalmic application): Burning, conjunctivitis, conjunctival hyperemia, corneal ulcers, irritation, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, systemic lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10527191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sulfacetamide, any component, or sulfonamides; infants &lt;2 months of age; epithelial herpes simplex keratitis, vaccinia, varicella, and other viral diseases of the cornea and conjunctiva; fungal diseases of the ocular structures",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10527194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with severe dry eye or G-6-PD deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10527193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antibacterial activity may be decreased in the presence of purulent exudates containing para-aminobenzoic acid (PABA); nonsusceptible organisms such as fungi may proliferate with prolonged or repeated use of sulfonamide preparations; hemolysis may occur in patients with G-6-PD deficiency. Hypersensitivity reactions may occur when a sulfonamide is readministered, irrespective of the route of administration. At the first sign of hypersensitivity, skin rash, or other reactions, inform physician and discontinue use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9523151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9523129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9523130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use of systemic sulfonamides during pregnancy may cause kernicterus in the newborn. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10527201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Response to therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10527197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial growth by inhibiting bacterial folic acid synthesis through competitive antagonism of PABA",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10527198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Improvement of conjunctivitis is usually seen within 3-6 days",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10527202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/55/18292?source=see_link\">",
"      see \"Sulfacetamide (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Eye drops may burn and sting when first instilled; may cause sensitivity to bright light",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lohr JA, Austin RD, Grossman M, et al, &ldquo;Comparison of Three Topical Antimicrobials for Acute Bacterial Conjunctivitis,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1988, 7(9):626-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?18/13/18643/abstract-text/2845348/pubmed\" id=\"2845348\" target=\"_blank\">",
"        2845348",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16049 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-564C5304BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18643=[""].join("\n");
var outline_f18_13_18643=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523096\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523097\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527189\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527199\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523211\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523099\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527200\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527196\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527190\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523083\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523149\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527191\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527194\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527193\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300089\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523151\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523129\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9523130\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527201\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527197\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527198\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10527202\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16049\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16049|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/61/32723?source=related_link\">",
"      Sulfacetamide (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/55/18292?source=related_link\">",
"      Sulfacetamide (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/42/26276?source=related_link\">",
"      Sulfacetamide (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/37/40531?source=related_link\">",
"      Sulfacetamide (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/16/38147?source=related_link\">",
"      Sulfacetamide (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_13_18644="Cystic hygroma CT V";
var content_f18_13_18644=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64341%7EPULM%2F69861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64341%7EPULM%2F69861&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a cystic mass in the anterior mediastinum, which displaces the trachea and esophagus against the spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic hygroma in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An MR scan, T2-weighted spin echo sequence shows a cystic mass in the anterior mediastinum, which displaces the trachea and esophagus against the spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18644=[""].join("\n");
var outline_f18_13_18644=null;
var title_f18_13_18645="Triprolidine and pseudoephedrine: Patient drug information";
var content_f18_13_18645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Triprolidine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/40/35462?source=see_link\">",
"     see \"Triprolidine and pseudoephedrine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/59/7093?source=see_link\">",
"     see \"Triprolidine and pseudoephedrine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F231800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aprodine [OTC];",
"     </li>",
"     <li>",
"      Pediatex&reg; TD;",
"     </li>",
"     <li>",
"      Silafed [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Actifed&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691980",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nose stuffiness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to triprolidine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad heart disease or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11130 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18645=[""].join("\n");
var outline_f18_13_18645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231800\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231801\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021644\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021646\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021645\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021650\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021651\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021653\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021648\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021649\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021654\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021655\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/40/35462?source=related_link\">",
"      Triprolidine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/59/7093?source=related_link\">",
"      Triprolidine and pseudoephedrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_13_18646="Pop fossa";
var content_f18_13_18646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Anatomy of the popliteal fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18646=[""].join("\n");
var outline_f18_13_18646=null;
var title_f18_13_18647="Dietary sources calcium and vitamin D PI";
var content_f18_13_18647=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Foods and drinks with calcium and vitamin D",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 574px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foods rich in calcium include ice cream, soy milk, breads, kale, broccoli, milk, cheese, cottage cheese, almonds, yogurt, ready-to-eat cereals, beans, and tofu. Foods rich in vitamin D include milk, canned tuna fish, cod liver oil, yogurt, ready-to-eat-cereals, cooked salmon, canned sardines, mackerel, and eggs. Some of these foods are rich in both.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18647=[""].join("\n");
var outline_f18_13_18647=null;
var title_f18_13_18648="Prevention and management of meconium aspiration syndrome";
var content_f18_13_18648=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and management of meconium aspiration syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18648/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18648/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18648/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18648/contributors\">",
"     Steven A Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18648/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18648/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/13/18648/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meconium aspiration syndrome (MAS) is defined as respiratory distress in newborn infants born through meconium-stained amniotic fluid (MSAF) whose symptoms cannot be otherwise explained [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/1\">",
"     1",
"    </a>",
"    ]. MAS can present with varying degrees of severity from mild respiratory distress to life-threatening respiratory failure. Coordination of care between the obstetric and neonatal team is important to reduce the incidence of MAS, and identify and provide emergent therapy in those who develop MAS to reduce morbidity and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention, management, and outcome of MAS will be reviewed here. The pathophysiology, clinical features, and diagnosis of MAS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182584917\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the potential for poor outcome, the best approach for managing meconium aspiration syndrome (MAS) is prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182584924\">",
"    <span class=\"h2\">",
"     Intrapartum management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intrapartum care to reduce the incidence of MAS includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prevention of fetal hypoxia that is thought to be an important contributor to the pathogenesis of MAS (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Pathophysiology'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Prevention of postmature ( &gt;41 or 42 weeks gestation) delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182584932\">",
"    <span class=\"h3\">",
"     Prevention of fetal hypoxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous or periodic intrapartum fetal heart rate (FHR) monitoring has become a standard of care in the United States, particularly in pregnancies thought to be at higher risk for intrapartum fetal hypoxemia (eg, postterm pregnancy, intrauterine growth restriction, preeclampsia). Evaluation and interventions are implemented in cases with abnormal tracings indicative of fetal stress. Although the combination of a nonreassuring FHR tracing and thick meconium in amniotic fluid has been associated with an increased risk of MAS, the value of intrapartum fetal monitoring to predict fetal hypoxemia and subsequent intervention in cases with abnormal traces in preventing MAS has not been proven. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182585387\">",
"    <span class=\"h3\">",
"     Prevention of postmature delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the risk of MAS is greatest in infants with a gestational age greater than 41 weeks, preventing delivery after 41 weeks gestation reduces the incidence of MAS. For women greater than 41 weeks of gestation, we suggest induction of labor rather than expectant management. Evidence demonstrating a decreased incidence of MAS due to a reduction in the number of postmature births is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=see_link&amp;anchor=H8#H8\">",
"     \"Postterm pregnancy\", section on 'Management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31142?source=see_link&amp;anchor=H9#H9\">",
"     \"Postterm infant\", section on 'Neonatal complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182584939\">",
"    <span class=\"h3\">",
"     Amnioinfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amnioinfusion, the instillation of isotonic fluid into the amniotic cavity, has been advocated to improve neonatal outcome in women laboring with thick meconium in the amniotic fluid. The proposed benefits of amnioinfusion include dilution of thick clumps of meconium by the instilled fluid, and possible prevention or relief of cord compression. However, it remains unclear whether or not amnioinfusion reduces meconium-related neonatal morbidity. As a result, amnioinfusion is",
"    <strong>",
"     not",
"    </strong>",
"    recommended as a routine approach to mothers with meconium-stained amniotic fluid (MSAF). The indications for amnioinfusion including its role in mothers with thick meconium are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=see_link\">",
"     \"Amnioinfusion: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182585429\">",
"    <span class=\"h2\">",
"     Delivery room management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182586550\">",
"    <span class=\"h3\">",
"     Obstetrical care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of meconium-stained amniotic fluid (MSAF), it had been common practice for obstetrical care providers to aspirate the upper airways on the perineum in an attempt to reduce the risk of MAS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. However, the 2005 American Heart Association Neonatal Resuscitation Guidelines and the Society of Obstetricians and Gynecologists of Canada do",
"    <strong>",
"     not",
"    </strong>",
"    recommend routine intrapartum suctioning for meconium-stained infants based on evidence from a large randomized controlled trial that did not find a benefit of intrapartum suctioning in infants with MSAF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this study, 2514 infants of at least 37 weeks gestation with cephalic (vertex) presentation and MSAF of any consistency were randomly assigned to suctioning of the oropharynx, nasopharynx, and hypopharynx or no suctioning before delivery of the shoulders. Suctioning was performed with a 10- to 13-Fr suction catheter connected to negative pressure of 150 mmHg. Postnatal delivery room management was in accordance with the concurrent 2000 Neonatal Resuscitation program guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/4\">",
"     4",
"    </a>",
"    ] and provided by clinicians blinded to the allocation group. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of MAS did not differ between groups (4 percent in both).",
"     </li>",
"     <li>",
"      There were no significant differences between the control and section groups detected in any of the secondary outcomes: the need for mechanical ventilation for MAS (1 versus 2 percent), mortality (&le;1 percent in both groups), duration of mechanical ventilation (four versus five days), duration of oxygen therapy (five versus six days), or length of hospital stay (eight versus nine days).",
"     </li>",
"     <li>",
"      No complications of suctioning were noted.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lack of benefit from intrapartum suctioning may be because events leading to MAS occur in-utero or before delivery of the shoulders, and thus are not affected by oropharyngeal suctioning by the obstetrician during delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182584961\">",
"    <span class=\"h3\">",
"     Neonatal care",
"    </span>",
"    &nbsp;&mdash;&nbsp;After delivery, the guidelines from the International Liaison Committee on Resuscitation (ILCOR) and the American Heart Association (AHA)",
"    <strong>",
"     no",
"    </strong>",
"    longer recommend suctioning in the",
"    <strong>",
"     vigorous",
"    </strong>",
"    infant with MSAF as it does not improve outcome and may cause complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      This was illustrated in a trial in which 2094 infants &ge;37 weeks gestational age, born through MSAF of any consistency, and apparently vigorous at birth, were randomly assigned to have tracheal intubation and suctioning or to be managed expectantly [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/3\">",
"       3",
"      </a>",
"      ]. Rates of MAS (3.2 versus 2.7 percent) and other respiratory disorders (3.8 versus 4.5 percent) did not differ between groups. Of the 1098 infants who were successfully intubated, including 64 in the expectantly managed group, 3.8 percent had complications that usually were transient. These included bradycardia, hoarseness or stridor, and laryngospasm.",
"     </li>",
"     <li>",
"      A meta-analysis reported similar results that tracheal suctioning was not shown to be superior to routine resuscitation in vigorous term meconium-stained infants [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It remains uncertain whether tracheal suctioning is beneficial in nonvigorous neonates with MSAF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Because of the lack of sufficient evidence to recommend a change in practice, the",
"    <span class=\"nowrap\">",
"     ILCOR/AHA",
"    </span>",
"    guidelines continue to recommend tracheal suctioning of residual meconium be performed in",
"    <strong>",
"     nonvigorous",
"    </strong>",
"    (depressed) infants (ie, absent or depressed respirations, decreased muscle tone, or heart rate less than 100",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    with MSAF [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In these patients, direct laryngoscopy is performed immediately after birth to suction the hypopharynx under direct vision and to intubate and suction the trachea. Endotracheal suctioning should be performed before applying positive pressure ventilation in infants who develop apnea or respiratory distress, even if they are vigorous initially. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link&amp;anchor=H11#H11\">",
"     \"Neonatal resuscitation in the delivery room\", section on 'Meconium stained amniotic fluid'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182584976\">",
"    <span class=\"h4\">",
"     Post-delivery room",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who develop MAS exhibit signs of respiratory distress immediately after birth. In a study of 394 term infants with MSAF, MAS developed in 18 of 96 patients with Apgar scores &lt;8 (19 percent) and in 1 of 298 patients with an Apgar score &ge;9 (0.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/14\">",
"     14",
"    </a>",
"    ]. All 19 patients with MAS had signs of respiratory distress within 15 minutes of birth, which required ventilatory support in 16 of the infants. These results demonstrate that full-term infants with MSAF without any sign of respiratory distress or depression immediately after birth are unlikely to develop MAS.",
"   </p>",
"   <p>",
"    As a result, in our practice, infants with MSAF who exhibit signs of respiratory distress in the delivery room are observed in the neonatal intensive care unit or Special Care Nursery for four to six hours to ensure they transition successfully. Asymptomatic infants with Apgar scores &ge;9 can be admitted to the normal nursery without additional monitoring or intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the management of meconium aspiration syndrome (MAS) is largely supportive, the prompt identification and care of affected patients have decreased morbidity and mortality, especially in patients with severe disease. Coordination of care between the obstetric and neonatal team is crucial to initiate effective management of infants who develop MAS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The general approach to care includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintenance of adequate oxygenation and ventilation",
"     </li>",
"     <li>",
"      Maintenance of adequate blood pressure and perfusion",
"     </li>",
"     <li>",
"      Correction of any metabolic abnormality including hypoglycemia and acidosis, which increase oxygen consumption",
"     </li>",
"     <li>",
"      Empirical antibiotic therapy",
"     </li>",
"     <li>",
"      Care in a neutral thermal environment (unless there are signs of hypoxemic ischemic encephalopathy, which is treated with hypothermia) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link&amp;anchor=H16#H16\">",
"       \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\", section on 'Therapeutic hypothermia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Minimal handling of the infant to avoid agitation, which exacerbates persistent pulmonary hypertension of the newborn (PPHN), if present (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182586256\">",
"    <span class=\"h2\">",
"     Respiratory management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory management is focused on maintaining optimal oxygenation and ventilation, especially as hypoxemia, acidosis, and hypercapnia may increase pulmonary vascular resistance and contribute to the development of PPHN. Hyperventilation, respiratory alkalosis, and air-trapping should be avoided.",
"   </p>",
"   <p>",
"    Supplemental oxygen therapy is usually adequate in patients with mild or moderate disease. In patients with severe disease, interventions may include mechanical ventilation, high frequency ventilation, surfactant therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inhaled nitric oxide therapy. In patients with respiratory failure who have failed to respond to other interventions, extracorporeal membrane oxygenation (ECMO) may be a life-saving intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Oxygen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen therapy should be initiated to keep the infant well saturated (SaO2 &gt;99 percent) while diagnostic tests are performed. When the diagnosis is established, arterial PO2 should be maintained in the range of 55 to 90 mmHg (SaO2 &gt;90 percent) to provide adequate tissue oxygenation and avoid lung injury that may result from continued administration of high concentrations of oxygen. Hypoxemia should be avoided because it contributes to pulmonary vasoconstriction and possibly PPHN. Umbilical arterial and venous (multiple lumen) catheters are used to monitor arterial blood gases and blood pressure and infuse fluids and medications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=see_link\">",
"     \"Continuous oxygen delivery systems for infants, children, and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link\">",
"     \"Oxygen monitoring and therapy in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Assisted ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assisted ventilation is used when gas exchange is not adequate with spontaneous breathing. When FiO2 exceeds 0.4 to 0.5, continuous positive airway pressure (CPAP) may improve oxygenation. CPAP should be used cautiously in infants with hyperinflation as it may exacerbate air trapping. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=see_link&amp;anchor=H4#H4\">",
"     \"Oxygen monitoring and therapy in the newborn\", section on 'Oxygen delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 30 percent of patients with MAS require mechanical ventilation due to respiratory failure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The goal for assisted ventilation is to achieve optimal gas exchange with minimal respiratory trauma. In infants with MAS, we typically target PaCO2 levels between 50 to 55 mmHg and arterial PO2 between 55 to 90 mmHg (SaO2 &gt;90 percent). We consider using high frequency oscillatory ventilation in infants who fail to respond to conventional mechanical ventilation, and in those who fail mechanical ventilation and pharmacologic treatment, ECMO therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H3#H3\">",
"     \"Mechanical ventilation in neonates\", section on 'Indications for ventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=see_link&amp;anchor=H10#H10\">",
"     \"Mechanical ventilation in neonates\", section on 'High frequency ventilation'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H182586447\">",
"     'Extracorporeal membrane oxygenation (ECMO)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182586360\">",
"    <span class=\"h4\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with MAS may breathe out of synchrony with the ventilator, which may aggravate agitation. Agitation may be associated with catecholamine release, increased pulmonary vascular resistance, right-to-left shunting, and hypoxemia.",
"   </p>",
"   <p>",
"    The goal of sedative therapy is maintain effective and safe sedation to achieve optimal gas exchange during the acute phase of the illness and allow for controlled weaning from assisted ventilation.",
"   </p>",
"   <p>",
"    In these patients, we use an opioid analgesic for sedation and analgesia including the following agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35114?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention and treatment of neonatal pain\", section on 'Systemic analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32233?source=see_link\">",
"       morphine sulfate",
"      </a>",
"      (loading dose of 100 to 150",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      over one hour, followed by a continuous infusion of 10 to 20",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/45/35546?source=see_link\">",
"       fentanyl",
"      </a>",
"      (1 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per hour)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If dyssynchronous breathing persists and a specific cause cannot be identified (eg, airway obstruction or air leak), we may use neuromuscular blockade with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/0/34821?source=see_link\">",
"     pancuronium",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV push per dose). However, we limit this intervention as much as possible because of potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Surfactant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surfactant may reduce the severity of respiratory disease and reduce the need for ECMO in mechanically ventilated infants with MAS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/17\">",
"     17",
"    </a>",
"    ]. This was illustrated in a meta-analysis of four trials that included 326 infants. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in mortality rate between infants who received surfactant compared to placebo (RR 0.98, 95% CI 0.41-2.39).",
"     </li>",
"     <li>",
"      In two studies that enrolled 208 infants, surfactant reduced the need for ECMO therapy (RR 0.64, 95% CI 0.46-0.91).",
"     </li>",
"     <li>",
"      Surfactant compared to placebo did not reduce the risk of pneumothorax (three studies), pulmonary interstitial emphysema (one study), chronic lung disease (one study), air leaks (one study), duration of mechanical ventilation (three studies) or oxygen therapy (two studies), or intraventricular hemorrhage (two studies).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    routinely administer surfactant to all patients with MAS. However, we will administer surfactant (150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <span class=\"nowrap\">",
"     [6mL/kg])",
"    </span>",
"    to patients with severe disease who are mechanically ventilated and require high FiO2 (&gt;0.5) and high mean airway pressure (&gt;10 to 12 cmH2O) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/18\">",
"     18",
"    </a>",
"    ]. Surfactant may also be helpful in infants with radiographic evidence of surfactant dysfunction (eg, low lung volumes and homogeneous pulmonary parenchymal disease that is similar in appearance to RDS).",
"   </p>",
"   <p>",
"    We do",
"    <strong>",
"     not",
"    </strong>",
"    routinely recommend tracheobronchial lavage with surfactant. Although data are limited, the use of this modality may be warranted in centers without ECMO capabilities and who are experienced in performing this intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one clinical trial of 66 ventilated infants with MAS, there was no difference in the use of high frequency ventilation and the nitric oxide between patients treated with surfactant lavage and those who received standard care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/20\">",
"     20",
"    </a>",
"    ]. The mortality rate was lower in the lavage group compared with the control group (10 versus 31 percent). However, lung lavage with surfactant in preterm ventilated infants is technically demanding and is associated with serious complications. Further studies confirming the efficacy of this therapy in larger randomized control trials is required before lavage with surfactant can be routinely recommended for infants with severe MAS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182586440\">",
"    <span class=\"h3\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that may improve oxygenation in patients with associated PPHN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H23#H23\">",
"     \"Persistent pulmonary hypertension of the newborn\", section on 'Inhaled nitric oxide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another pulmonary vasodilator agent used in the treatment of PPHN is",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/9/38041?source=see_link\">",
"     sildenafil",
"    </a>",
"    , a phosphodiesterase inhibitor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link&amp;anchor=H27#H27\">",
"     \"Persistent pulmonary hypertension of the newborn\", section on 'Potential agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H182586447\">",
"    <span class=\"h3\">",
"     Extracorporeal membrane oxygenation (ECMO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECMO may be life-saving in infants who do not respond to mechanical ventilation, surfactant therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    iNO [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. ECMO provides cardiopulmonary support while awaiting resolution of the underlying pulmonary disease process without further risk of injury from volutrauma from mechanical ventilation and the use of high concentrations of supplemental oxygen.",
"   </p>",
"   <p>",
"    Both venovenous and venoarterial ECMO have been used in infants with meconium aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/24\">",
"     24",
"    </a>",
"    ]. Although both methods are invasive compared with the medical treatments for MAS, venoarterial ECMO requires ligation of the carotid artery and may be associated with complications of pulmonary emboli from the ECMO circuit and increased left ventricular afterload. The addition of other therapeutic modalities, such as surfactant and iNO, has allowed the successful use of venovenous ECMO in infants with MAS, thus avoiding the more invasive venoarterial procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Circulatory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapeutic measures that insure adequate cardiac output and tissue perfusion include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maintaining sufficient intravascular volume. Volume expansion using normal saline may be needed in infants with low blood pressure and inadequate tissue perfusion. Enteral feeds are not provided during severe respiratory illness. Parenteral fluids are generally given at a restricted rate of 65",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per day. In the first 24 hours, no electrolytes are added to the parenteral fluids. Subsequently, sodium intake is limited to minimize peripheral and pulmonary edema.",
"     </li>",
"     <li>",
"      Transfusion of packed red blood cells may be required to optimize tissue oxygen delivery, especially in patients with marginal oxygenation. In general, we maintain hemoglobin concentration above 15",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (hematocrit above 40 to 45 percent) in severe MAS.",
"     </li>",
"     <li>",
"      Vasopressor support often is needed to maintain adequate blood pressure. We begin with a continuous intravenous infusion of dopamine (2.5 to 10",
"      <span class=\"nowrap\">",
"       micrograms/kg",
"      </span>",
"      per min IV) and increase the infusion rate as necessary to maintain normal mean arterial blood pressure. Blood pressure may need to be higher in infants with PPHN to minimize right-to-left shunting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the risk of infection and the difficulty of distinguishing between meconium aspiration syndrome and bacterial pneumonia, we begin broad-spectrum antibiotics (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/38/38503?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    ) while awaiting the results of blood cultures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical features and diagnosis of meconium aspiration syndrome\", section on 'Infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=see_link\">",
"     \"Treatment and outcome of sepsis in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Corticosteroid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although corticosteroid therapy has been proposed to reduce the severity of MAS, there is",
"    <strong>",
"     no",
"    </strong>",
"    evidence of its effectiveness in infants with MAS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. As a result, we do",
"    <strong>",
"     not",
"    </strong>",
"    recommend the use of corticosteroid therapy in patients with MAS unless future control trials demonstrate significant benefit from its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall outcome of meconium aspiration syndrome (MAS) has improved with advances in neonatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective review from a multi-center study from the United States that included 162,075 term infants born between 1997 and 2007, 1.8 percent of patients developed MAS [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/16\">",
"     16",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the 7518 infants with MAS, 82 percent were discharged home from a nonintensive care setting, 7.9 percent required transfer for intensive care, and 1.2 percent died (n = 88).",
"     </li>",
"     <li>",
"      Extracorporeal membrane oxygenation (ECMO) treatment was performed in 61 neonates (1.4 percent) including three infants who died.",
"     </li>",
"     <li>",
"      Multivariate analysis showed mortality was independently associated with an Apgar score less than 3 (OR 7.5, 95% CI 4.6-12.2), need for ventilatory support within the first 48 hours of life (OR 4.1, 95% CI 2.1-8.1), repeated doses of vasopressive agents (OR 3.8, 95% CI 2.2-6.4), presence of a major congenital anomaly (OR 2.1, 95% CI 1.4-3.4), and the use of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/23/40310?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (OR 2.1, 95% CI 1.4-3.4).",
"     </li>",
"     <li>",
"      The short-term morbidity of survivors included oxygen supplementation at 28 days of life (5 percent), seizures (5 percent), and four patients developed necrotizing enterocolitis. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this study, the mortality rate of 1.2 percent was lower in comparison to 4.2 percent that was reported in a large retrospective study from the United States of 176,790 infants born between 1973 and 1987 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary morbidity, especially reactive airway disease, appears to be common in patients who had MAS, as illustrated by three small follow-up studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/27-29\">",
"     27-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary outcome was evaluated in 35 infants with MAS and 70 controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/29\">",
"       29",
"      </a>",
"      ]. During the first six months after birth, the infants with MAS were significantly more likely to have one or more episodes of wheezing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      coughing lasting &ge;3 days (49 versus 20 percent) and receive bronchodilator therapy (23 versus 3 percent) compared to controls.",
"     </li>",
"     <li>",
"      Pulmonary function testing was performed at eight years of age in 11 children who had MAS and nine controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/28\">",
"       28",
"      </a>",
"      ]. The MAS group was more likely to have mild airway obstruction, hyperinflation, and increased closing volumes compared to controls, and had more exercise-induced bronchospasm (4 versus 0 children). However, during graded exercise stress tests, MAS children had normal maximal oxygen consumption and anaerobic threshold (also known as lactate threshold) without significant hypoxemia or hypercarbia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=see_link\">",
"       \"Exercise physiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory symptoms, pulmonary function tests, and chest radiographs were evaluated in 18 children ages 6 to 11 years who had MAS [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/27\">",
"       27",
"      </a>",
"      ]. Seven children had recurrent cough and wheezing consistent with asthma, and five of these had exercise-induced bronchospasm that responded to bronchodilators. Of the 11 asymptomatic children, two had mild expiratory airflow limitation, one had exercise-induced bronchospasm, and eight had normal pulmonary function. Chest radiographs were normal in all the children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neurologic outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are limited data on the neurodevelopmental outcome of patients with MAS. Small observational case series report that about 20 percent have significant neurodevelopmental impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18648/abstract/30\">",
"     30",
"    </a>",
"    ]. However, birth depression occurs in 20 to 30 percent of patient with MAS, and it is likely intrauterine asphyxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    infection that are the major underlying pathologic factors resulting in poor neurodevelopmental outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of neonatal encephalopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264557318\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meconium aspiration syndrome (MAS) is defined as respiratory distress in newborn infants born through meconium-stained amniotic fluid (MSAF) whose symptoms cannot be otherwise explained. In severe cases, MAS can be life-threatening. As a result, it is important to reduce the incidence of MAS and provide emergent therapy to reduce the mortality in those who develop MAS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interventions used to prevent MAS include the following:",
"     </li>",
"     <li>",
"      We suggest that intrapartum fetal heart rate (FHR) monitoring to detect episodes of fetal hypoxia be used in pregnancies with meconium-stained amniotic fluid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although fetal hypoxia is thought to contribute to the pathogenesis of MAS, the value of intrapartum fetal monitoring and subsequent intervention in cases with abnormal traces in preventing MAS has not been proven. (See",
"      <a class=\"local\" href=\"#H182584932\">",
"       'Prevention of fetal hypoxia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women &ge;41 weeks of gestation, we recommend induction rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182585387\">",
"       'Prevention of postmature delivery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=see_link&amp;anchor=H8#H8\">",
"       \"Postterm pregnancy\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dilution of thick meconium with amnioinfusion has not been shown to be effective in reducing the incidence of MAS. As a result, we do",
"      <strong>",
"       not",
"      </strong>",
"      suggest amnioinfusion as a routine intervention for mothers with meconium-stained amniotic fluid (MSAF) unless there are coincident variable fetal heart rate decelerations (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182584924\">",
"       'Intrapartum management'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=see_link&amp;anchor=H5#H5\">",
"       \"Amnioinfusion: Indications\", section on 'Meconium stained amniotic fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      At delivery, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend intrapartum suction for MSAF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H182586550\">",
"       'Obstetrical care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After delivery, we do",
"      <strong>",
"       not",
"      </strong>",
"      recommend endotracheal intubation and suctioning of vigorous newborn infants born through MSAF (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Endotracheal suctioning is reserved for nonvigorous infants with absent or depressed respirations, decreased muscle tone, or heart rate less than 100",
"      <span class=\"nowrap\">",
"       beats/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H182584961\">",
"       'Neonatal care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who develop MAS exhibit signs of respiratory distress immediately after birth. In our practice, infants with MSAF who exhibit signs of respiratory distress in the delivery room are typically observed in the neonatal intensive care unit or Special Care Nursery for four to six hours to ensure that they transition successfully. Asymptomatic infants with Apgar scores &ge;9 are admitted to the normal nursery without additional monitoring or intervention. (See",
"      <a class=\"local\" href=\"#H182584976\">",
"       'Post-delivery room'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of MAS is supportive. In our practice, we suggest the following approach (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maintenance of adequate oxygenation and ventilation &ndash; Respiratory management is focused on maintaining adequate oxygenation and ventilation, especially as hypoxemia, acidosis, and hypercapnia may increase pulmonary vascular resistance and contribute to the development of persistent pulmonary hypertension (PPHN). Supplemental oxygen therapy is usually adequate in patients with mild or moderate disease. In patients with severe disease, interventions may include mechanical ventilation, surfactant therapy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      inhaled nitric oxide therapy. In patients with respiratory failure who have failed to response to other interventions, extracorporeal membrane oxygenation may be a lifesaving intervention. (See",
"      <a class=\"local\" href=\"#H182586256\">",
"       'Respiratory management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintenance of adequate blood pressure and perfusion with sufficient vascular volume, and in some patients, the use of vasopressor agents, such as dopamine. Transfusion of packed red blood cells is also required to replace blood lost from sampling and to optimize tissue oxygen delivery. In our practice, the hemoglobin level is generally maintained at 15",
"      <span class=\"nowrap\">",
"       g/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Circulatory support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Correction of any metabolic abnormality including hypoglycemia, acidosis,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      electrolyte derangements.",
"     </li>",
"     <li>",
"      The administration of empirical antibiotic therapy while awaiting the results of blood cultures because it is difficult to differentiate MAS from bacterial pneumonia and sepsis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Care in a neutral thermal environment for infants without evidence of hypoxic-ischemic encephalopathy.",
"     </li>",
"     <li>",
"      Minimal handling of the infant to avoid agitation, which PPHN, if present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"       \"Persistent pulmonary hypertension of the newborn\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mortality rate of MAS has improved because of advances in neonatal care. In survivors, long-term morbidity includes pulmonary sequelae, particularly reactive airway disease, and neurodevelopmental impairment. However, it is likely that intrauterine hypoxia and chronic infection, which are possible contributors to MAS, are the major underlying factors that result in poor neurodevelopmental outcome in patients with MAS. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/1\">",
"      Fanaroff AA. Meconium aspiration syndrome: historical aspects. J Perinatol 2008; 28 Suppl 3:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/2\">",
"      Bhutani VK. Developing a systems approach to prevent meconium aspiration syndrome: lessons learned from multinational studies. J Perinatol 2008; 28 Suppl 3:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/3\">",
"      Wiswell TE, Gannon CM, Jacob J, et al. Delivery room management of the apparently vigorous meconium-stained neonate: results of the multicenter, international collaborative trial. Pediatrics 2000; 105:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/4\">",
"      Niermeyer S, Kattwinkel J, Van Reempts P, et al. International Guidelines for Neonatal Resuscitation: An excerpt from the Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: International Consensus on Science. Contributors and Reviewers for the Neonatal Resuscitation Guidelines. Pediatrics 2000; 106:E29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/5\">",
"      Wiswell TE, Henley MA. Intratracheal suctioning, systemic infection, and the meconium aspiration syndrome. Pediatrics 1992; 89:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/6\">",
"      Carson BS, Losey RW, Bowes WA Jr, Simmons MA. Combined obstetric and pediatric approach to prevent meconium aspiration syndrome. Am J Obstet Gynecol 1976; 126:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/7\">",
"      Vain NE, Szyld EG, Prudent LM, et al. Oropharyngeal and nasopharyngeal suctioning of meconium-stained neonates before delivery of their shoulders: multicentre, randomised controlled trial. Lancet 2004; 364:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/8\">",
"      Roggensack A, Jefferies AL, Farine D, et al. Management of meconium at birth. J Obstet Gynaecol Can 2009; 31:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/9\">",
"      Kattwinkel J, Perlman JM, Aziz K, et al. Neonatal resuscitation: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Pediatrics 2010; 126:e1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/10\">",
"      American Heart Association, American Academy of Pediatrics. 2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: neonatal resuscitation guidelines. Pediatrics 2006; 117:e1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/11\">",
"      Halliday HL. Endotracheal intubation at birth for preventing morbidity and mortality in vigorous, meconium-stained infants born at term. Cochrane Database Syst Rev 2001; :CD000500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/12\">",
"      Kattwinkel J. Neonatal resuscitation guidelines for ILCOR and NRP: evaluating the evidence and developing a consensus. J Perinatol 2008; 28 Suppl 3:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/13\">",
"      Wiswell TE. Delivery room management of the meconium-stained newborn. J Perinatol 2008; 28 Suppl 3:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/14\">",
"      van Ierland Y, de Boer M, de Beaufort AJ. Meconium-stained amniotic fluid: discharge vigorous newborns. Arch Dis Child Fetal Neonatal Ed 2010; 95:F69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/15\">",
"      Wiswell TE, Tuggle JM, Turner BS. Meconium aspiration syndrome: have we made a difference? Pediatrics 1990; 85:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/16\">",
"      Singh BS, Clark RH, Powers RJ, Spitzer AR. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year period. J Perinatol 2009; 29:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/17\">",
"      El Shahed AI, Dargaville P, Ohlsson A, Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007; :CD002054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/18\">",
"      Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996; 97:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/19\">",
"      Lam BC, Yeung CY. Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 1999; 103:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/20\">",
"      Dargaville PA, Copnell B, Mills JF, et al. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr 2011; 158:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/21\">",
"      Davis PJ, Shekerdemian LS. Meconium aspiration syndrome and extracorporeal membrane oxygenation. Arch Dis Child Fetal Neonatal Ed 2001; 84:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/22\">",
"      Friedlich P, Noori S, Stein J, et al. Predictability model of the need for extracorporeal membrane oxygenation in neonates with meconium aspiration syndrome treated with inhaled nitric oxide. J Pediatr Surg 2005; 40:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/23\">",
"      Radhakrishnan RS, Lally PA, Lally KP, Cox CS Jr. ECMO for meconium aspiration syndrome: support for relaxed entry criteria. ASAIO J 2007; 53:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/24\">",
"      Kugelman A, Gangitano E, Taschuk R, et al. Extracorporeal membrane oxygenation in infants with meconium aspiration syndrome: a decade of experience with venovenous ECMO. J Pediatr Surg 2005; 40:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/25\">",
"      Yeh TF, Srinivasan G, Harris V, Pildes RS. Hydrocortisone therapy in meconium aspiration syndrome: a controlled study. J Pediatr 1977; 90:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/26\">",
"      Ward M, Sinn J. Steroid therapy for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev 2003; :CD003485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/27\">",
"      Macfarlane PI, Heaf DP. Pulmonary function in children after neonatal meconium aspiration syndrome. Arch Dis Child 1988; 63:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/28\">",
"      Swaminathan S, Quinn J, Stabile MW, et al. Long-term pulmonary sequelae of meconium aspiration syndrome. J Pediatr 1989; 114:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/29\">",
"      Yuksel B, Greenough A, Gamsu HR. Neonatal meconium aspiration syndrome and respiratory morbidity during infancy. Pediatr Pulmonol 1993; 16:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18648/abstract/30\">",
"      Beligere N, Rao R. Neurodevelopmental outcome of infants with meconium aspiration syndrome: report of a study and literature review. J Perinatol 2008; 28 Suppl 3:S93.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5011 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18648=[""].join("\n");
var outline_f18_13_18648=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H264557318\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H182584917\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182584924\">",
"      Intrapartum management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182584932\">",
"      - Prevention of fetal hypoxia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182585387\">",
"      - Prevention of postmature delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182584939\">",
"      - Amnioinfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182585429\">",
"      Delivery room management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182586550\">",
"      - Obstetrical care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182584961\">",
"      - Neonatal care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H182584976\">",
"      Post-delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H182586256\">",
"      Respiratory management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Assisted ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H182586360\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Surfactant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182586440\">",
"      - Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H182586447\">",
"      - Extracorporeal membrane oxygenation (ECMO)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Circulatory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Corticosteroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary sequelae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neurologic outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H264557318\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/8/5252?source=related_link\">",
"      Amnioinfusion: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2442?source=related_link\">",
"      Clinical features, diagnosis, and treatment of neonatal encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/24/27014?source=related_link\">",
"      Continuous oxygen delivery systems for infants, children, and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/35/25144?source=related_link\">",
"      Exercise physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/39/4729?source=related_link\">",
"      Mechanical ventilation in neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29656?source=related_link\">",
"      Oxygen monitoring and therapy in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/26/31142?source=related_link\">",
"      Postterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16535?source=related_link\">",
"      Postterm pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35114?source=related_link\">",
"      Prevention and treatment of neonatal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26200?source=related_link\">",
"      Treatment and outcome of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_13_18649="Epidemiology of tuberculosis";
var content_f18_13_18649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology of tuberculosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18649/contributors\">",
"     C Robert Horsburgh, Jr, MD, MUS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18649/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18649/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/13/18649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of the epidemiology of Mycobacterium tuberculosis is critical for effective control. The global burden of tuberculosis (TB), risk factors for transmission, and the epidemiology of TB in the United States will be reviewed here. The epidemiology of drug-resistant TB is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=see_link\">",
"     \"Epidemiology and molecular mechanisms of drug-resistant tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6462182\">",
"    <span class=\"h1\">",
"     M. TUBERCULOSIS COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. tuberculosis is a member of the Mycobacterium tuberculosis complex; other members include Mycobacterium africanum and Mycobacterium bovis.",
"   </p>",
"   <p>",
"    M. africanum is most commonly found in West African countries; it causes up to a quarter of cases of tuberculosis (TB) in the Gambia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/1\">",
"     1",
"    </a>",
"    ]. The symptoms of infection resemble those of M. tuberculosis. The infectivity is similar to M. tuberculosis, and it is an important opportunistic pathogen in the setting of advanced immunosuppression due to HIV or other causes. Management is identical to management for disease due to M. tuberculosis.",
"   </p>",
"   <p>",
"    M. bovis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16614?source=see_link\">",
"     \"Mycobacterium bovis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GLOBAL BURDEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 2 billion people (about one-third of the world population) are estimated to be infected with Mycobacterium tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/2\">",
"     2",
"    </a>",
"    ]. The global incidence of tuberculosis (TB) peaked around 2003 and appears to be declining slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ]. According to the World Health Organization (WHO), in 2010, 8.8 million individuals became ill with TB and 1.4 million died [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/4\">",
"     4",
"    </a>",
"    ]. Both these statistics reflect a decline compared with prior years. The number of individuals infected with TB peaked in 2005, when 9 million individuals became ill. The death peaked at 1.8 million in 2003.",
"   </p>",
"   <p>",
"    The epidemiology of TB varies substantially around the world (",
"    <a class=\"graphic graphic_figure graphicRef55097 \" href=\"UTD.htm?27/12/27846\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75602 \" href=\"UTD.htm?27/36/28239\">",
"     table 1",
"    </a>",
"    ). The highest rates",
"    <span class=\"nowrap\">",
"     (100/100,000",
"    </span>",
"    or higher) are observed in sub-Saharan Africa, India, China, and the islands of Southeast Asia and Micronesia. Intermediate rates of TB (26 to 100",
"    <span class=\"nowrap\">",
"     cases/100,000)",
"    </span>",
"    occur in Central and South America, Eastern Europe, and northern Africa. Low rates (less than 25 cases per 100,000 inhabitants) occur in the United States, Western Europe, Canada, Japan, and Australia.",
"   </p>",
"   <p>",
"    Poverty, HIV, and drug resistance are major contributors to the resurging global TB epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Approximately 95 percent of TB cases occur in developing countries. Approximately 1 in 14 new TB cases occur in individuals who are infected with HIV; 85 percent of these cases occur in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ]. An estimated half million cases of multidrug resistant (MDR)-TB also occur annually.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Strategies and targets for control",
"    </span>",
"    &nbsp;&mdash;&nbsp;After decades of relative neglect, global efforts to control TB were reinvigorated in 1991 when a World Health Assembly resolution recognized TB as a major global health problem [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/7\">",
"     7",
"    </a>",
"    ]. The five-element DOTS (Directly Observed Therapy, Short-course) strategy was developed by the WHO as a response in the mid 1990s; the components included [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Government commitment to TB control",
"     </li>",
"     <li>",
"      Case detection among symptomatic patients",
"     </li>",
"     <li>",
"      Standardized chemotherapy for all sputum smear-positive cases under proper case management conditions",
"     </li>",
"     <li>",
"      Regular drug supply",
"     </li>",
"     <li>",
"      Monitoring system for program supervision and evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The DOTS framework was subsequently implemented in 184 countries. This change vastly improved the quality and outreach of national TB programs. By 2006 over 25 of the 32 million patients treated in DOTS programs worldwide were cured [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several challenges emerged during the implementation of DOTS that were not fully addressed in the original World Health Assembly recommendations. To address these problems, a new plan entitled Stop TB Partnership: The Global Plan to Stop TB 2006-2015 was developed by the WHO and its partners [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In addition to enhancing the original elements of DOTS (with a stronger focus on diagnostic accuracy and patient-centered treatment adherence), the following additional control components included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Collaborative activities implemented jointly by TB and",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      programs",
"     </li>",
"     <li>",
"      New treatment strategies to manage MDR-TB",
"     </li>",
"     <li>",
"      New community approaches to engage all relevant partners in national TB program implementation, for expansion of equitable access to diagnosis and treatment",
"     </li>",
"     <li>",
"      Health system strengthening to address impediments to national TB program implementation (eg, limited human resources, financial and managerial capabilities)",
"     </li>",
"     <li>",
"      The Global Drug Facility and the Green Light Committee to improve global access to affordable and quality-assured first- and second-line drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intensified research to develop better TB diagnosis, prevention and treatment tools",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These components were designed to address new \"Millennium Development Goals\" (MDG) for TB control and prevention. These goals are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To halt and reverse the trend of rising incidence of TB by 2015",
"     </li>",
"     <li>",
"      To halve the 1990 prevalence of TB and death rates due to TB by 2015",
"     </li>",
"     <li>",
"      To reduce the worldwide incidence of TB to &le;1 per million by 2050",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Epidemiologists have used mathematical models to predict that detection of at least 70 percent of the incident cases of infectious TB and cure of at least 85 percent of cases are needed to reduce TB incidence, prevalence, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Therefore, the two most important targets for achieving TB control are to detect at least 70 percent of new TB cases and to achieve a treatment success rate of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the models mentioned above do not account for common and real problems such as treatment delays, relapses, or changes in vulnerability to infection or strain virulence.",
"   </p>",
"   <p>",
"    Other important goals (not explicitly included in the above programs) include reducing the number of patients with infected with strains of MDR-TB, increasing the number of TB patients who are tested for HIV, increasing the number of HIV-infected TB patients enrolled on antiretroviral treatment, and increasing the number of HIV-infected individuals enrolled in treatment for latent TB infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Progress toward targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progress has been made in achieving the first MDG target (to halt and reverse rising trends in the incidence of TB). This goal has been wholly or partially achieved in most regions of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There has been less success in achieving the second MDG target (to halve the prevalence and death rates due to TB present in 1990 by the year 2015). However, some progress has been achieved. For example, if the rate of improvement seen from 2001-2006 in prevalence and death rates in the Americas, eastern Mediterranean, Southeast Asia and western Pacific regions continues during the period 2006 and 2014, the second MDG goal will be achieved. Unfortunately, this goal will not be achieved by 2015 in the African and European regions at the current rates of improvement.",
"   </p>",
"   <p>",
"    One difficulty in achieving the goals described is that a dramatic TB resurgence occurred in some areas during the 1990s. In Africa, this resurgence was largely due to the HIV epidemic, but it was also compounded by poor access to health services [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/18\">",
"     18",
"    </a>",
"    ]. In Eastern Europe, this resurgence can be attributed to widespread economic decline, secondary declines in the overall quality of health services, poor living conditions, alcoholism, and the emergence of infection due to MDR strains of M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The third MDG target (to reduce the incidence of TB to &lt;1 case per million by 2050) appears to be unachievable at this time. An annual decline of 15 percent in the worldwide incidence of TB is required to meet this goal. Even with complete implementation of all the control measures advocated by the World Health Agency, the third MDG target goal cannot be achieved by 2050.",
"   </p>",
"   <p>",
"    As noted above, the two most important targets for TB control have been to reach at least 70 percent case detection and 85 percent treatment success [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ]. Case detection rates are highest in western Pacific, Americas, and Southeast Asia (68 to 70 percent) and lowest in Africa, Europe, and the eastern Mediterranean (46 to 52 percent). Asia and Africa account for the majority of global cases of TB (55 and 31 percent, respectively). Two thirds of the \"missing cases\" occur in China, India, and Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on treatment success rates follow similar geographic patterns, although these rates reflect only the proportion of patients who received treatment. It is sometimes uncertain whether these patients completed an effective treatment course. The western Pacific, Americas, and Southeast Asia have had the greatest success (78 to 92 percent); Africa, Europe, and the eastern Mediterranean have fared less well (70 to 83 percent). Success is limited in part by the high prevalence of HIV infection in Africa and drug resistance in Eastern Europe.",
"   </p>",
"   <p>",
"    Most patients who are coinfected with TB and HIV are not recognized to be coinfected. For example, the worldwide percentage of patients with TB disease who underwent subsequent HIV testing improved only marginally (from 1 to 12 percent) during the time period 2002 to 2006. The significance of this failure to test for",
"    <span class=\"nowrap\">",
"     TB/HIV",
"    </span>",
"    coinfection is important, as the proportion of coinfected patients has risen steeply in sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In Zimbabwe, for example, the number of patients treated for TB increased 10-fold from the 1980s to 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/23\">",
"     23",
"    </a>",
"    ]. Yet only 22 percent of the patients from Zimbabwe identified as having TB during this time span underwent testing for HIV coinfection, despite the fact that Zimbabwe has been known to have a high prevalence of HIV for decades. The authors of the cited study estimated that approximately one in four Zimbabwean patients coinfected with HIV and TB was identified as coinfected.",
"   </p>",
"   <p>",
"    Detection and treatment of MDR-TB is also inadequate. Among the patients tested in 27 countries with high rates of MDR-TB, only about 5 percent of the estimated number of MDR-TB cases in these countries were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ]. Treatment rates range from 60 to 69 percent of those identified in countries with programs endorsed by the Green Light Committee (GLC) and 28 to 36 percent in countries without GLC-approved projects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/3\">",
"     3",
"    </a>",
"    ]. As noted above, however, these treatment rates reflect only the proportion of patients who received treatment; it is uncertain whether these patients completed an effective treatment course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Socioeconomic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Socioeconomic development and access to quality of health services appear to be at least as important as any specific TB control measure. The likelihood of success of TB control efforts is likely related to socioeconomic indicators, including gross domestic product per capita, mortality of children &lt;5, access to clean water, and adequate sanitation and health expenditure per capita.",
"   </p>",
"   <p>",
"    The importance of addressing these socioeconomic factors to achieve TB control is reinforced by the fact that many countries have experienced a rapid decline in TB burden without good access to high-quality TB treatment. In Europe, for example, TB morbidity and mortality declined long before effective chemotherapy was available, largely because of socioeconomic development, improved living conditions, better nutrition, and isolation of infectious cases in sanatoria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     IN THE UNITED STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a marked decline in the incidence of tuberculosis (TB) in the United States over several decades, the incidence rose in the period 1985-1992 (",
"    <a class=\"graphic graphic_figure graphicRef75420 \" href=\"UTD.htm?4/2/4142\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Since 1992 there has been a substantial decline in the rate of TB; in 2012 it fell to an historic low of 3.2 per 100,000 (",
"    <a class=\"graphic graphic_figure graphicRef66025 \" href=\"UTD.htm?30/44/31438\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. The 11.4 percent decrease between 2009 and 2008 was the greatest single year decrease ever recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/34\">",
"     34",
"    </a>",
"    ]. The success in reducing the burden of TB in the United States reflects several factors including improved public health efforts, physician and patient education, infection control measures, and use of directly observed therapy.",
"   </p>",
"   <p>",
"    A majority of TB cases in the United States now occurs in foreign-born individuals emigrating from countries with high rates of endemic TB (57 percent of United States TB cases in 2006; the case rate in this group is 22 per 100,000). Of these cases, roughly half occur in individuals residing in the United States for &le;5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/35\">",
"     35",
"    </a>",
"    ]. RFLP analysis has demonstrated that most of these cases are due to reactivation of latent infection rather than transmission within communities [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. Therefore, screening for and treatment of latent infection can be a useful prevention tool among foreign-born individuals.",
"   </p>",
"   <p>",
"    Increased travel and immigration of individuals from countries with endemic TB are certain to bring new challenges to TB control. In 2000 it was estimated that 11 million individuals with latent TB (with capacity for future reactivation) reside in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/42\">",
"     42",
"    </a>",
"    ]. The countries accounting for the majority of cases of TB in foreign-born persons in the United States are Mexico, the Philippines, Vietnam, India, and China, the Dominican Republic and Haiti. The states accounting for the greatest number of US cases are California, New York, New Jersey, Texas and Florida (",
"    <a class=\"graphic graphic_figure graphicRef66885 \" href=\"UTD.htm?3/23/3441\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/27,43\">",
"     27,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-associated TB accounts for approximately 10 percent of TB cases in the United States; among TB patients between 25 and 44 years of age, 22 percent are known to be HIV infected. According to data from the United States National TB Surveillance System for 1993-2005, about 9 percent of TB patients were HIV-seropositive; 69 percent of TB patients in the United States received HIV testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/28\">",
"     28",
"    </a>",
"    ]. HIV infection rates in TB patients were highest among injection drug users, homeless persons, correctional facility inmates and alcoholics (35, 22, 16, and 15 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18203424\">",
"    <span class=\"h2\">",
"     Seasonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis in the United States has been shown to be seasonal, with a peak in the spring and a trough in the fall (",
"    <a class=\"graphic graphic_figure graphicRef83979 \" href=\"UTD.htm?7/5/7256\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/44\">",
"     44",
"    </a>",
"    ]. Latitude-dependent factors, including reduced winter sunlight and its potential effect on vitamin D levels, do not appear to contribute significantly to seasonality in the United States. Instead, seasonality appears to be greater among clustered cases and children, groups in whom disease likely reflects recent transmission of tuberculosis. Therefore tuberculosis disease resulting from recent infection with early progression to disease appears to be more influenced by season than disease that results from activation of latent tuberculosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for TB may be divided as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired immunity (host factors)",
"     </li>",
"     <li>",
"      Increased exposure to infectious persons (environmental factors)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Host factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Categories of host factors are outlined in the following sections. The relative risk for selected risk factors is outlined below. The relative importance of different risk factors varies with prevalence of exposure across regions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Substance abuse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance abuse is the most commonly reported behavioral risk factor among patients with TB in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug use &mdash; The epidemiologic factors associated with injection and non-injection drug use (eg, homelessness, incarceration) contribute to the high prevalence of TB among drug users [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/46-51\">",
"       46-51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tobacco &mdash; Cigarette smoking confers a relative risk of about 1.5 to 2.0 for the development of tuberculosis (TB) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. Smoking has been found to be associated with both risk of relapse of TB and TB mortality. Passive smoking also increases the risk for TB [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Alcohol &mdash; The risk of active TB is substantially elevated in individuals who consume more than 40 g alcohol per day [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/55\">",
"       55",
"      </a>",
"      ]. This may be due to the effect of alcohol and alcohol-related conditions on the immune system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malnutrition is generally understood to be an important risk factor for TB, although the relation between impaired immunity due to malnutrition and risk of acquiring TB has not been well characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/56-60\">",
"     56-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Underweight &mdash; Persons who are underweight (body mass index of &lt;18.5) have increased risk for TB by a factor of 2.6 (1.2 to 4.8) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/56,57\">",
"       56,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Vitamin D &mdash; Vitamin D plays an important role in macrophage activation and restriction of mycobacterial growth, and diminished serum vitamin D levels appear to increase risk for TB infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/61-66\">",
"       61-66",
"      </a>",
"      ]. Among African immigrants in Australia, for example, individuals with latent or active TB were observed to have substantially lower serum vitamin D levels than those without TB [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iron status &mdash; Iron is an important growth factor for M. tuberculosis in macrophages and appears to play an important role in host susceptibility to TB infection [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Systemic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diseases discussed in this section have been noted to confer some degree of increased risk for TB reactivation. However, in some cases it can be difficult to discern the relative risk of systemic diseases for development of active TB, since many studies were performed in areas where the prevalence of TB is relatively low.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Silicosis &mdash; The risk of TB is increased among miners with silicosis. The mechanism is not fully understood but may be related to impairment of pulmonary macrophage function by silica crystals. The relative risk depends on the severity of the silicosis and has been estimated at 1.4 to 2.9 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/68-70\">",
"       68-70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Malignancy &mdash; The risk of TB is increased in patients with hematologic malignancies and head and neck cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/71\">",
"       71",
"      </a>",
"      ]. In a 25 year review of cancer patients in the United States, the rate of TB among patients with hematologic neoplasms was &gt;200 cases per 100,000 persons, or about 40 times the rate among the general population. Among patients with head and neck cancer, the rate was &gt;100 cases per 100,000 persons. It is important to note that these studies were performed in areas where the prevalence of TB is relatively low.",
"      <br/>",
"      <br/>",
"      Patients with solid tumors other than head and neck cancer do not have an increased risk for TB; among these individuals the rate paralleled that of the general population.",
"     </li>",
"     <li>",
"      Diabetes &mdash; The risk of developing tuberculosis increases with increasing diabetes severity [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/72\">",
"       72",
"      </a>",
"      ]. A case control study of 5290 patients demonstrated that poorly controlled diabetes confers a 2.9-fold increase in the risk of developing pulmonary TB; the risk associated with well-controlled diabetes was minimal [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/73\">",
"       73",
"      </a>",
"      ]. The mechanism by which diabetes confers an altered immune response to M. tuberculosis is not fully understood but may be related in part to altered cytokine expression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal disease &mdash; The risk of TB among patients with chronic renal disease risk is 6.9 to 52.5 times that of individuals without renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/75,76\">",
"       75,76",
"      </a>",
"      ]. Uremia causes reduced cellular immunity. Other factors that may diminish immunity in the setting of renal failure include malnutrition, vitamin D deficiency, and hyperparathyroidism.",
"     </li>",
"     <li>",
"      Gastric surgery &mdash; Gastric resection for peptic ulcer disease has been described as a risk factor for TB (relative risk 1.7 to 2.0) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/77,78\">",
"       77,78",
"      </a>",
"      ]. Although this procedure is no longer performed routinely, gastric bypass is a similar procedure that may confer similar risk [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/79\">",
"       79",
"      </a>",
"      ]. The mechanism is not understood but may be related to loss of gastric acidity; however, the risk of TB among persons with gastric achlorhydria has not been studied.",
"     </li>",
"     <li>",
"      Celiac disease &mdash; Celiac disease (autoimmune inflammation of the small intestine) is a risk factor for TB; the mechanism is not fully understood but may be related to malabsorption [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/80\">",
"       80",
"      </a>",
"      ]. In a study of two national registries, the risk of TB was significantly higher among 14,335 individuals with a prior diagnosis of celiac disease than among the 69,888 matched controls (hazard ratio 3.74).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Immune compromise",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV &mdash; HIV infection markedly increases the risk for primary and reactivation TB; the magnitude of risk is likely variable depending on the degree of HIV-induced immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/18,43,73,81\">",
"       18,43,73,81",
"      </a>",
"      ]. Among HIV-seropositive individuals the risk of acquiring TB is 9 to16 times that of HIV-seronegative individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/82,83\">",
"       82,83",
"      </a>",
"      ]. The risk of TB decreases with initiation of antiretroviral therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Glucocorticoids &mdash; Patients receiving a daily dose of &ge;15 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (or its equivalent) for &ge;1 month are at increased risk for TB [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/86\">",
"       86",
"      </a>",
"      ]. A case-control study in the United Kingdom including more than 16 million person-years of TB risk demonstrated that patients with TB were 4.9 times more likely to have been using glucocorticoids than those without TB [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TNF inhibitors &mdash; Tumor necrosis factor (TNF)-alpha inhibitors (used in the treatment of rheumatic diseases and inflammatory bowel disease) impair host resistance to TB. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transplant &mdash; Renal, cardiac, liver, and allogeneic stem cell transplants are all associated with increased risk for TB [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/88-91\">",
"       88-91",
"      </a>",
"      ]. The risk in allogeneic stem cell transplants is less than in solid organ transplant patients; there does not appear to be an increased risk of TB in autologous stem cell transplant patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Age and gender",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; In the developing world TB rates are highest among young adults, reflecting primary transmission in this age group. In the United States and other developed countries, the rate of TB among the elderly is higher than among younger adults and children, reflecting reactivation disease, possibly attributable to impaired immunity with aging.",
"     </li>",
"     <li>",
"      Gender &mdash; The rate of TB is higher among men than women, beginning in the young adult years and persisting throughout life. This is a longstanding observation thought to reflect more frequent TB exposure in the community among men than women [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Social and environmental factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Household contacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close household contact with an individual with smear-positive pulmonary TB is the most important risk factor for TB [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/11,93\">",
"     11,93",
"    </a>",
"    ]. In a study of TB contact investigation including 1080 smear-positive patients and their 6225 close contacts, 36 percent of contacts had positive tuberculin skin tests [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/94\">",
"     94",
"    </a>",
"    ]; this compares to an expected skin-test positive rate of only 2.9 percent in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Birth in a TB-endemic area",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fraction of TB cases in the United States ascribed to foreign born individuals increased from 22 to 58 percent between 1986 and 2007 (",
"    <a class=\"graphic graphic_figure graphicRef66025 \" href=\"UTD.htm?30/44/31438\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/27,95\">",
"     27,95",
"    </a>",
"    ]. The risk of TB is highest in the first five years after immigration, but remains higher than the United States-born population for up to 20 years after arrival [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/35\">",
"     35",
"    </a>",
"    ]. Seven countries account for the majority of cases of TB in foreign-born persons in the United States: Mexico, the Philippines, Vietnam, India, and China, the Dominican Republic and Haiti [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/35,95,96\">",
"     35,95,96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overseas screening for TB among United States-bound immigrants and refugees is a high-yield intervention for identifying TB and could reduce the number of TB cases among foreign-born persons in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. Between 1999 and 2005, the prevalence of smear negative and latent TB cases among immigrants was 961 and 837 cases per 100,000, respectively; the prevalence of these entities among refugees was 1036 and 2838 per 100,000 respectively. Active pulmonary TB and latent TB were diagnosed in the United States in 7 and 1.6 percent of those with overseas diagnoses, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Community settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In places where contact with infectious individuals may occur, risk for acquiring TB infection is increased. Crowding and poor ventilation can increase the risk of transmission in such settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/99-106\">",
"     99-106",
"    </a>",
"    ]. Those at risk for increased exposure include residents and employees of congregate settings such as hospitals, correctional facilities, nursing homes, and homeless shelters. Among 1289 inmates incarcerated in 16 Maryland prisons in 1997, the incidence of tuberculin skin conversion was 6.3 infections per 100 person-years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/99\">",
"     99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Socioeconomic status",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB has traditionally been associated with low socioeconomic status, which also may be associated with crowding, poor nutrition, poor access to medical care, public assistance, unemployment, and low education [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Minority groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;TB disease rates among racial and ethnic minority groups are 5 to 10 times higher than among whites; these groups comprised 83 percent of all reported TB cases in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18649/abstract/28\">",
"     28",
"    </a>",
"    ]. Among non-Hispanic whites, Hispanics, non-Hispanic blacks and Asians, rates were 1.1, 8.4, 9.3 and 25.8 per 100,000, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25489?source=see_link\">",
"       \"Patient information: Tuberculosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=see_link\">",
"       \"Patient information: Tuberculosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 2 billion people (about one-third of the world population) are estimated to be infected with tuberculosis (TB). The global incidence of TB peaked around 2003 and appears to be been declining slowly. In 2006 the World Health Organization (WHO) estimated that the prevalence of active disease was 14.4 million, a prevalence rate of",
"      <span class=\"nowrap\">",
"       219/100,000",
"      </span>",
"      persons. The incidence of new cases was 9.2 million, an incidence rate of",
"      <span class=\"nowrap\">",
"       139/100,000.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Global burden'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poverty, HIV, and drug resistance fan the flames of the TB epidemic. Worldwide, about 95 percent of TB cases occur in developing countries. Among all new TB cases in 2006, about 7 percent were estimated to be HIV infected; 85 percent of these cases occur in Africa. In that year there were an estimated half million cases of multidrug resistant (MDR)-TB; the rate was highest in Eastern Europe. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Global burden'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The five-element DOTS (Directly Observed Therapy, Short-course) strategy was developed by the World Health Organization (WHO) in the mid 1990s. To address several challenges emerged during the implementation of DOTS, a new plan entitled Stop TB Partnership: The Global Plan to Stop TB 2006-2015 was outlined by WHO. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Strategies and targets for control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The first Millennium Development Goals (MDG) target (to halt and reverse TB incidence) has likely been met in most regions, although the other two MDG targets (to halve 1990 prevalence and death rates by 2015 and to reduce TB incidence to &le;1 per million by 2050) are greater challenges. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Progress toward targets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Socioeconomic development and access and quality of health services appear to be at least as important as any specific TB control measure. Risk factors for TB may be divided into issues related to host immunity (eg, immunologic defects that lead to increased susceptibility to infection) and issues related to environmental exposure to infection (eg, risk of exposure to a case of infectious TB). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Socioeconomic factors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A majority of TB cases in the United States occurs in foreign-born individuals emigrating from countries with high rates of endemic TB. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'In the United States'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/1\">",
"      de Jong BC, Antonio M, Gagneux S. Mycobacterium africanum--review of an important cause of human tuberculosis in West Africa. PLoS Negl Trop Dis 2010; 4:e744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/2\">",
"      L&ouml;nnroth K, Raviglione M. Global epidemiology of tuberculosis: prospects for control. Semin Respir Crit Care Med 2008; 29:481.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Global Tuberculosis control. WHO/HTM/TB/2008.393. Geneva: World Health Organization; 2008. file://www.who.int/tb/publications/global_report/2008/en/index.html (Accessed on December 08, 2011).",
"    </li>",
"    <li>",
"     The WHO Global tuberculosis control report. file://bit.ly/rlO0ti. (Accessed on January 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/5\">",
"      Corbett EL, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006; 367:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/6\">",
"      Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet 2009; 373:1861.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. Forty-fourth World Health Assembly. WHA44/1991/REC/1. Geneva: WHO; 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/8\">",
"      Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002; 359:775.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. WHO Tuberculosis Programme-Framework for Effective Tuberculosis Control file://www.who.int/tb/publications/1994/en/index.html (Accessed on December 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/10\">",
"      Raviglione MC, Uplekar MW. WHO's new Stop TB Strategy. Lancet 2006; 367:952.",
"     </a>",
"    </li>",
"    <li>",
"     WHO. The Stop TB Strategy: Building on and Enhancing DOTS to meet the TB-Related Millennium Develpment Goals file://www.who.int/tb/publications/2006/en/ (Accessed on December 08, 2011).",
"    </li>",
"    <li>",
"     Stop TB Partnership. The Global Plan to Stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva: World Health Organization; 2006a file://www.who.int/tb/publications/2006/en/ (Accessed on December 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/13\">",
"      Maher D, Dye C, Floyd K, et al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ 2007; 85:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/14\">",
"      Matiru R, Ryan T. The Global Drug Facility: a unique, holistic and pioneering approach to drug procurement and management. Bull World Health Organ 2007; 85:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/15\">",
"      Gupta R, Cegielski JP, Espinal MA, et al. Increasing transparency in partnerships for health--introducing the Green Light Committee. Trop Med Int Health 2002; 7:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/16\">",
"      Dye C, Garnett GP, Sleeman K, Williams BG. Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy. Lancet 1998; 352:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/17\">",
"      Borgdorff MW, Floyd K, Broekmans JF. Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries. Bull World Health Organ 2002; 80:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/18\">",
"      Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/19\">",
"      Walberg P, McKee M, Shkolnikov V, et al. Economic change, crime, and mortality crisis in Russia: regional analysis. BMJ 1998; 317:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/20\">",
"      Leon DA, Chenet L, Shkolnikov VM, et al. Huge variation in Russian mortality rates 1984-94: artefact, alcohol, or what? Lancet 1997; 350:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/21\">",
"      Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/22\">",
"      Lawn SD, Bekker LG, Middelkoop K, et al. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/23\">",
"      Corbett EL, Muzangwa J, Chaka K, et al. Nursing and community rates of Mycobacterium tuberculosis infection among students in Harare, Zimbabwe. Clin Infect Dis 2007; 44:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/24\">",
"      Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev 2001; 23:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/25\">",
"      Burzynski J, Schluger NW. The epidemiology of tuberculosis in the United States. Semin Respir Crit Care Med 2008; 29:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/26\">",
"      Khan K, Wang J, Hu W, et al. Tuberculosis infection in the United States: national trends over three decades. Am J Respir Crit Care Med 2008; 177:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/27\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/28\">",
"      Centers for Disease Control and Prevention (CDC). Reported HIV status of tuberculosis patients--United States, 1993-2005. MMWR Morb Mortal Wkly Rep 2007; 56:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/29\">",
"      Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. N Engl J Med 1995; 333:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/30\">",
"      Centers for Disease Control and Prevention (CDC). Decrease in reported tuberculosis cases - United States, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis--United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/32\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/33\">",
"      Centers for Disease Control and Prevention (CDC). Trends in tuberculosis - United States, 2012. MMWR Morb Mortal Wkly Rep 2013; 62:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Assessment of declines in reported tuberculosis cases--Georgia and Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2011; 60:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/35\">",
"      Cain KP, Haley CA, Armstrong LR, et al. Tuberculosis among foreign-born persons in the United States: achieving tuberculosis elimination. Am J Respir Crit Care Med 2007; 175:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/36\">",
"      Geng E, Kreiswirth B, Driver C, et al. Changes in the transmission of tuberculosis in New York City from 1990 to 1999. N Engl J Med 2002; 346:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/37\">",
"      Chin DP, DeRiemer K, Small PM, et al. Differences in contributing factors to tuberculosis incidence in U.S. -born and foreign-born persons. Am J Respir Crit Care Med 1998; 158:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/38\">",
"      Tornieporth NG, Ptachewich Y, Poltoratskaia N, et al. Tuberculosis among foreign-born persons in New York City, 1992-1994: implications for tuberculosis control. Int J Tuberc Lung Dis 1997; 1:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/39\">",
"      Borgdorff MW, Behr MA, Nagelkerke NJ, et al. Transmission of tuberculosis in San Francisco and its association with immigration and ethnicity. Int J Tuberc Lung Dis 2000; 4:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/40\">",
"      Jasmer RM, Ponce de Leon A, Hopewell PC, et al. Tuberculosis in Mexican-born persons in San Francisco: reactivation, acquired infection and transmission. Int J Tuberc Lung Dis 1997; 1:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/41\">",
"      Walter ND, Jasmer RM, Grinsdale J, et al. Reaching the limits of tuberculosis prevention among foreign-born individuals: a tuberculosis-control program perspective. Clin Infect Dis 2008; 46:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/42\">",
"      Bennett DE, Courval JM, Onorato I, et al. Prevalence of tuberculosis infection in the United States population: the national health and nutrition examination survey, 1999-2000. Am J Respir Crit Care Med 2008; 177:348.",
"     </a>",
"    </li>",
"    <li>",
"     Horsburgh CR, Moore M, Castro KG. Epidemiology of tuberculosis in the United States. In: Tuberculosis, 2nd, Rom WN, Garay SM.  (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/44\">",
"      Willis MD, Winston CA, Heilig CM, et al. Seasonality of tuberculosis in the United States, 1993-2008. Clin Infect Dis 2012; 54:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/45\">",
"      Oeltmann JE, Kammerer JS, Pevzner ES, Moonan PK. Tuberculosis and substance abuse in the United States, 1997-2006. Arch Intern Med 2009; 169:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/46\">",
"      Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis 2009; 48:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/47\">",
"      Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989; 320:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/48\">",
"      Durante AJ, Selwyn PA, O'Connor PG. Risk factors for and knowledge of Mycobacterium tuberculosis infection among drug users in substance abuse treatment. Addiction 1998; 93:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/49\">",
"      Daley CL, Hahn JA, Moss AR, et al. Incidence of tuberculosis in injection drug users in San Francisco: impact of anergy. Am J Respir Crit Care Med 1998; 157:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/50\">",
"      Pevzner ES, Robison S, Donovan J, et al. Tuberculosis transmission and use of methamphetamines in Snohomish County, WA, 1991-2006. Am J Public Health 2010; 100:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/51\">",
"      Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med 2011; 364:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/52\">",
"      Bates MN, Khalakdina A, Pai M, et al. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007; 167:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/53\">",
"      Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med 2009; 180:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/54\">",
"      Leung CC, Lam TH, Ho KS, et al. Passive smoking and tuberculosis. Arch Intern Med 2010; 170:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/55\">",
"      L&ouml;nnroth K, Williams BG, Stadlin S, et al. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health 2008; 8:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/56\">",
"      PALMER CE, JABLON S, EDWARDS PQ. Tuberculosis morbidity of young men in relation to tuberculin sensitivity and body build. Am Rev Tuberc 1957; 76:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/57\">",
"      Edwards LB, Livesay VT, Acquaviva FA, Palmer CE. Height, weight, tuberculous infection, and tuberculous disease. Arch Environ Health 1971; 22:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/58\">",
"      Tverdal A. Body mass index and incidence of tuberculosis. Eur J Respir Dis 1986; 69:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/59\">",
"      Leung CC, Lam TH, Chan WM, et al. Lower risk of tuberculosis in obesity. Arch Intern Med 2007; 167:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/60\">",
"      Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis 2004; 8:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/61\">",
"      Chandra G, Selvaraj P, Jawahar MS, et al. Effect of vitamin D3 on phagocytic potential of macrophages with live Mycobacterium tuberculosis and lymphoproliferative response in pulmonary tuberculosis. J Clin Immunol 2004; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/62\">",
"      Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn HJ. Reactivation of tuberculosis and vitamin D deficiency: the contribution of diet and exposure to sunlight. Thorax 2007; 62:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/63\">",
"      Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/64\">",
"      Ustianowski A, Shaffer R, Collin S, et al. Prevalence and associations of vitamin D deficiency in foreign-born persons with tuberculosis in London. J Infect 2005; 50:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/65\">",
"      Gibney KB, MacGregor L, Leder K, et al. Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis 2008; 46:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/66\">",
"      Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 2011; 108:19013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/67\">",
"      Boelaert JR, Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host's iron status on tuberculosis. J Infect Dis 2007; 195:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/68\">",
"      Cowie RL. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 1994; 150:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/69\">",
"      Corbett EL, Churchyard GJ, Clayton TC, et al. HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners. AIDS 2000; 14:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/70\">",
"      Kleinschmidt I, Churchyard G. Variation in incidences of tuberculosis in subgroups of South African gold miners. Occup Environ Med 1997; 54:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/71\">",
"      Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis 2006; 42:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/72\">",
"      Baker MA, Lin HH, Chang HY, Murray MB. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012; 54:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/73\">",
"      Pablos-M&eacute;ndez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/74\">",
"      Restrepo BI, Fisher-Hoch SP, Pino PA, et al. Tuberculosis in poorly controlled type 2 diabetes: altered cytokine expression in peripheral white blood cells. Clin Infect Dis 2008; 47:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/75\">",
"      Hussein MM, Mooij JM, Roujouleh H. Tuberculosis and chronic renal disease. Semin Dial 2003; 16:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/76\">",
"      Pien FD, Younoszai BG, Pien BC. Mycobacterial infections in patients with chronic renal disease. Infect Dis Clin North Am 2001; 15:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/77\">",
"      THORN PA, BROOKES VS, WATERHOUSE JA. Peptic ulcer, partial gastrectomy, and pulmonary tuberculosis. Br Med J 1956; 1:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/78\">",
"      Steiger Z, Nickel WO, Shannon GJ, et al. Pulmonary tuberculosis after gastric resection. Am J Surg 1976; 131:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/79\">",
"      Bruce RM, Wise L. Tuberculosis after jejunoileal bypass for obesity. Ann Intern Med 1977; 87:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/80\">",
"      Ludvigsson JF, Wahlstrom J, Grunewald J, et al. Coeliac disease and risk of tuberculosis: a population based cohort study. Thorax 2007; 62:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/81\">",
"      Havlir DV, Getahun H, Sanne I, Nunn P. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA 2008; 300:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/82\">",
"      Guelar A, Gatell JM, Verdejo J, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993; 7:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/83\">",
"      Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/84\">",
"      Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/85\">",
"      Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/86\">",
"      Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161:S221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/87\">",
"      Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006; 55:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/88\">",
"      Lichtenstein IH, MacGregor RR. Mycobacterial infections in renal transplant recipients: report of five cases and review of the literature. Rev Infect Dis 1983; 5:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/89\">",
"      Mu&ntilde;oz P, Palomo J, Mu&ntilde;oz R, et al. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/90\">",
"      Meyers BR, Halpern M, Sheiner P, et al. Tuberculosis in liver transplant patients. Transplantation 1994; 58:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/91\">",
"      Akan H, Arslan O, Akan OA. Tuberculosis in stem cell transplant patients. J Hosp Infect 2006; 62:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/92\">",
"      Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis 1982; 125:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/93\">",
"      Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011; 377:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/94\">",
"      Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med 2000; 162:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/95\">",
"      Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA 1997; 278:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/96\">",
"      McKenna MT, McCray E, Jones JL, et al. The fall after the rise: Tuberculosis in the United States, 1991 through 1994. Am J Public Health 1998; 88:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/97\">",
"      Liu Y, Weinberg MS, Ortega LS, et al. Overseas screening for tuberculosis in U.S.-bound immigrants and refugees. N Engl J Med 2009; 360:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/98\">",
"      Barnett ED, Weld LH, McCarthy AE, et al. Spectrum of Illness in International Migrants Seen at GeoSentinel Clinics in 1997-2009, Part 1: US-Bound Migrants Evaluated by Comprehensive Protocol-Based Health Assessment. Clin Infect Dis 2013; 56:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/99\">",
"      MacIntyre CR, Kendig N, Kummer L, et al. Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons. Clin Infect Dis 1997; 24:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/100\">",
"      Stead WW, Lofgren JP, Warren E, Thomas C. Tuberculosis as an endemic and nosocomial infection among the elderly in nursing homes. N Engl J Med 1985; 312:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/101\">",
"      Schieffelbein CW Jr, Snider DE Jr. Tuberculosis control among homeless populations. Arch Intern Med 1988; 148:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/102\">",
"      Pablos-Mendez A, Raviglione MC, Battan R, Ramos-Zuniga R. Drug resistant tuberculosis among the homeless in New York City. N Y State J Med 1990; 90:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/103\">",
"      Centers for Disease Control (CDC). Drug-resistant tuberculosis among the homeless--Boston. MMWR Morb Mortal Wkly Rep 1985; 34:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/104\">",
"      Nolan CM, Elarth AM, Barr H, et al. An outbreak of tuberculosis in a shelter for homeless men. A description of its evolution and control. Am Rev Respir Dis 1991; 143:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/105\">",
"      Nardell E, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986; 315:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/106\">",
"      Centers for Disease Control and Prevention (CDC). Tuberculosis outbreak associated with a homeless shelter - Kane County, Illinois, 2007-2011. MMWR Morb Mortal Wkly Rep 2012; 61:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18649/abstract/107\">",
"      Cantwell MF, McKenna MT, McCray E, Onorato IM. Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998; 157:1016.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8018 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18649=[""].join("\n");
var outline_f18_13_18649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6462182\">",
"      M. TUBERCULOSIS COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GLOBAL BURDEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Strategies and targets for control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Progress toward targets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Socioeconomic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      IN THE UNITED STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18203424\">",
"      Seasonality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Host factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Substance abuse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Systemic diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Immune compromise",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Age and gender",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Social and environmental factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Household contacts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Birth in a TB-endemic area",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Community settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Socioeconomic status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Minority groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8018\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8018|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/12/27846\" title=\"figure 1\">",
"      World map of TB incidence (2009)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/2/4142\" title=\"figure 2\">",
"      United States TB epidemiology (1980 to 1991)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/44/31438\" title=\"figure 3\">",
"      United States TB case rates (1993 to 2009)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/23/3441\" title=\"figure 4\">",
"      United States map of TB case rates 2011",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/5/7256\" title=\"figure 5\">",
"      Seasonality of TB in US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8018|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/36/28239\" title=\"table 1\">",
"      Estimated TB incidence and prevalence by country",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7497?source=related_link\">",
"      Epidemiology and molecular mechanisms of drug-resistant tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/14/16614?source=related_link\">",
"      Mycobacterium bovis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/35/39475?source=related_link\">",
"      Patient information: Tuberculosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/57/25489?source=related_link\">",
"      Patient information: Tuberculosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=related_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_13_18650="Evaluation and diagnosis of mastocytosis (cutaneous and systemic)";
var content_f18_13_18650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Cem Akin, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/13/18650/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/13/18650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis describes a group of disorders in which pathologic mast cells accumulate in tissues. These diseases can be limited to the skin (cutaneous mastocytosis) or involve extracutaneous tissues (systemic mastocytosis).",
"   </p>",
"   <p>",
"    The evaluation and diagnosis of the different forms of cutaneous and systemic mastocytosis will be reviewed here. Other issues related to mastocytosis and the biology of mast cells are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=see_link\">",
"     \"Treatment and prognosis of systemic mastocytosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=see_link\">",
"     \"Mast cells: Surface receptors and signal transduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH TO THE PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation for a mast cell disorder is appropriate in a patient with manifestations of mast cell activation, such as flushing, tachycardia, diarrhea, fatigue or musculoskeletal pain, hypotensive syncope or near syncope affecting at least two organ systems. Patients may present with recurrent episodes of anaphylaxis or less severe symptoms suggestive of allergic reactions, for which no consistent trigger or cause has been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3577287\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms can be present in a daily basis or can be episodic. Each episode of symptoms that the patient can describe should be reviewed to determine if the signs and symptoms are consistent with mast cell activation. The physical exam must include a meticulous skin inspection to look for lesions of urticaria pigmentosa (",
"    <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"     picture 1",
"    </a>",
"    ) or mastocytomas (",
"    <a class=\"graphic graphic_picture graphicRef76891 \" href=\"UTD.htm?29/50/30497\">",
"     picture 2",
"    </a>",
"    ). Descriptions and additional images of characteristic skin lesions are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If lesions of urticaria pigmentosa are detected, then the examiner may lightly rub, scratch, or stroke a small area of the affected skin. The development of erythema or urticaria",
"    <span class=\"nowrap\">",
"     over/around",
"    </span>",
"    the lesion is called Darier's sign and is pathognomonic for the presence of mast cells within the lesion. However, lesions consistent with mastocytomas (localized accumulations of mast cells) (",
"    <a class=\"graphic graphic_picture graphicRef76891 \" href=\"UTD.htm?29/50/30497\">",
"     picture 2",
"    </a>",
"    ) should not be rubbed or scratched, as this may lead to generalized flushing and hives. Instead, the patient or caretaker can usually report that these symptoms occur if the lesion is disturbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lesions consistent with cutaneous mastocytosis should undergo a punch biopsy of skin lesions with specific histopathologic stains, if there is any doubt about the diagnosis. Skin biopsy findings in the context of the morphologic lesion are diagnostic of cutaneous mastocytosis, although skin biopsy does not provide information about systemic involvement. Patients who are not already taking an H1 antihistamine regularly should take a dose prior to biopsy to reduce the effects of mediator release during the procedure.",
"   </p>",
"   <p>",
"    Specimens should be fixed in formalin and undergo histopathologic staining with Giemsa",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunohistochemical staining for tryptase and c-kit. Techniques for identifying mast cells in tissues are presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link&amp;anchor=H10#H10\">",
"     \"Mast cells: Development, identification, and physiologic roles\", section on 'Cellular identification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Laboratories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following laboratory tests are recommended for a patient suspected of having mastocytosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Liver function tests (including serum aminotransferases and alkaline phosphatase)",
"     </li>",
"     <li>",
"      Serum tryptase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the measurement of metabolites of mast cell activation (including 24 hour urine for N-methyl histamine and 11-beta-prostaglandin F2) may be performed, to provide further evidence of mast cell activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19185617\">",
"    <span class=\"h2\">",
"     When to refer",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, the following patients should be referred to an",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    or hematology expert with knowledge of mast cell disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient suspected of having urticaria pigmentosa",
"     </li>",
"     <li>",
"      Patients with signs or symptoms suggestive of systemic mastocytosis",
"     </li>",
"     <li>",
"      Patients with elevated tryptase levels",
"     </li>",
"     <li>",
"      Patients with recurrent unexplained anaphylaxis with hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, among patients in whom the diagnosis of systemic mastocytosis has already been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those with mastocytosis and hematologic abnormalities should be referred to a hematologist for management of the hematologic disorder",
"     </li>",
"     <li>",
"      Those with aggressive mastocytosis should be referred to a hematologist for consideration of cytoreductive therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications for bone marrow examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be difficult to distinguish cutaneous from systemic mastocytosis solely on clinical grounds, since patients with cutaneous mastocytosis often have systemic symptoms caused by mast cell mediators and their actions on various tissues and organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is recommended that all adult patients with urticaria pigmentosa undergo bone marrow biopsy and aspiration, even if other signs and symptoms of systemic disease are not apparent, as the incidence of systemic disease in this population is high. In addition, patients with the symptoms or laboratory features below may be considered for workup for systemic mastocytosis regardless of the presence of skin lesions, particularly if there is an elevated baseline tryptase level.",
"   </p>",
"   <p>",
"    These symptoms and laboratory features include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unexplained flushing or anaphylaxis, particularly associated with documented hypotensive episodes",
"     </li>",
"     <li>",
"      Unexplained gastrointestinal abnormalities (eg, peptic ulcer disease, malabsorption, or diarrhea)",
"     </li>",
"     <li>",
"      Unexplained peripheral blood abnormalities",
"     </li>",
"     <li>",
"      Unexplained hepatomegaly, splenomegaly, or lymphadenopathy",
"     </li>",
"     <li>",
"      Unexplained pathologic bone fractures, osteopenia, osteoporosis or osteosclerosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Evaluation of common presentations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A simple bone marrow biopsy with histologic studies is less likely to be diagnostic of clonal mast cell disease in patients with serum tryptase levels &lt;20",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    These patients should be offered referral to a mast cell disease research center with expertise in diagnosing mastocytosis, since pathognomic clustering of mast cells may be absent in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow biopsy is not routinely performed in infants and children with cutaneous mastocytosis, unless there are specific findings to suggest extracutaneous organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/2\">",
"     2",
"    </a>",
"    ]. These include unexplained peripheral blood abnormalities, hepatomegaly, splenomegaly, or lymphadenopathy. This is a different approach from that recommended for adults.",
"   </p>",
"   <p>",
"    Rarely, cutaneous disease may first be diagnosed in adolescence. These patients are generally evaluated as childhood-onset mastocytosis, although they may have a higher likelihood of having systemic mastocytosis when compared to children whose lesions start within the first two years of life. Bone marrow evaluation for progression of disease to adult forms is indicated if skin lesions do not begin to regress or serum tryptase levels remain above the normal range (usually greater than 15",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signs and symptoms of the different types of systemic mastocytosis are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=see_link\">",
"     \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bone marrow studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow examination includes an evaluation of the histology of the core sample and of aspirated cells. Mast cells within the bone marrow core biopsy specimen are identified by immunohistochemical staining with antibodies to tryptase",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    c-kit receptor. Stains to detect CD25 should be performed, as mast cells in mastocytosis have pathologic expression of CD25. CD25 staining can be done in histopathology sections in most hospital pathology labs in formalin fixed bone marrow tissue. Metachromatic stains such as Giemsa or toluidine blue may fail to stain mast cells in the bone marrow core sections, as fixation and decalcification of the specimen can interfere with these stains. In addition, degranulated mast cells may lose their metachromatic staining properties.",
"   </p>",
"   <p>",
"    A sample from the bone marrow aspirate should be examined for morphologically abnormal mast cells (eg, spindle-shaped, hypogranular forms) and submitted for flow cytometric (FACS) analysis of mast cells. Mast cells are rare events in FACS evaluation of bone marrow (generally less than 0.1 percent of cells) and are identified by high expression of CD117 (c-kit receptor). Acquisition of at least one million cell events is preferred to capture enough mast cells.",
"   </p>",
"   <p>",
"    Expression of CD2 and CD25 should be assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Flow cytometry'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Analysis for KIT mutations should be performed. D816V KIT mutational analysis of bone marrow aspirates is commercially available in the United States, and it is also performed at several academic centers [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with leukocytosis, eosinophilia, or both, examination for",
"    <span class=\"nowrap\">",
"     BCR/ABL",
"    </span>",
"    and FIP1L1-PDGFRA fusion genes, as well as routine karyotyping, should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Myeloproliferative HES variants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Evaluation of common presentations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authorities have suggested the following practical guide to evaluation based upon age and clinical presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Urticaria pigmentosa in a child",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a child with skin lesions consistent with UP, initial evaluation includes the inspection of skin lesions, elicitation of Darier's sign, and the laboratories listed previously. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Initial approach to the patient'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A punch biopsy of the skin may be performed to confirm the diagnosis. Bone marrow examination is not necessary in children unless indicated by blood count or peripheral smear abnormalities, or other signs of an aggressive subtype (such as organomegaly, osteolyses, or others) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19185637\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adults may present in several different ways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Urticaria pigmentosa in an adult",
"    </span>",
"    &nbsp;&mdash;&nbsp;All adults with UP-like skin lesions should undergo a bone marrow examination, in addition to skin biopsy and the basic laboratories mentioned previously, as systemic disease is present in most adult patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4\">",
"     4",
"    </a>",
"    ]. A serum tryptase level, complete blood count with differential and liver function tests should also be checked.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Symptoms related to mast cell mediators, without skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with this presentation, basic laboratories mentioned previously and serum tryptase levels should be drawn. If tryptase levels are &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a bone marrow examination should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3581667\">",
"    <span class=\"h4\">",
"     Unexplained severe allergic or anaphylactic reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A serum tryptase level should be drawn for a patient presenting with unexplained allergic or anaphylactic-like reactions, particularly to a hymenoptera sting (regardless of whether skin testing to hymenoptera venom is positive or negative for IgE-mediated allergy). Anaphylactic reactions without hives should also raise the suspicion for systemic mastocytosis. If the tryptase is greater than 20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a repeat serum tryptase and the basic studies mentioned above should be performed a few weeks later. If this repeat level is also greater than 20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    a bone marrow examination should be pursued.",
"   </p>",
"   <p>",
"    Some experts recommend a bone marrow biopsy in all patients presenting with recurrent unexplained hypotensive anaphylactic episodes regardless of tryptase levels, as a subset of these patients may have clonal mast cell disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, patients with unexplained anaphylaxis should undergo a thorough allergy evaluation, including skin testing and in vitro testing for allergen-specific IgE based on history. Skin testing in patients with cutaneous and systemic mastocytosis has been reported to be safe and reliable, although it should not be performed on lesional skin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"     \"Idiopathic anaphylaxis\"",
"    </a>",
"    .) It should be noted that some of these patients may be on scheduled antihistamines which would interfere with skin testing, but antihistamines should not be discontinued for the sole purpose of skin testing unless it is determined to be safe by an allergy specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cutaneous forms of disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Laboratory results",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complete blood count and differential are typically normal in cutaneous forms of mastocytosis, although a mild eosinophilia is sometimes noted. Liver function tests should be normal. The sedimentation rate is usually normal, although it may be slightly elevated if extensive areas of skin are affected. Serum tryptase and urinary histamine are usually normal, although they may be elevated when the skin is diffusely involved, such as in bullous forms of diffuse cutaneous mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Histopathology of skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin biopsy establishes the diagnosis of cutaneous mastocytosis but does not specify the category (which is determined clinically) or provide information about the risk of systemic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. There are four patterns of mast cell infiltrates that are observed in cutaneous mastocytosis, which only partially correlate with the type of clinical lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Perivascular infiltrates in the papillary and upper dermis are increased",
"     </li>",
"     <li>",
"      Sheet-like infiltrates in the papillary body and upper reticular dermis",
"     </li>",
"     <li>",
"      Interstitial infiltrates",
"     </li>",
"     <li>",
"      Nodular infiltrates",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The phenotype of these mast cells is MCtc",
"    <span class=\"nowrap\">",
"     (tryptase/chymase/carboxypeptidase",
"    </span>",
"    A3 positive), which is also the predominant mast cell of normal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/15\">",
"     15",
"    </a>",
"    ]. Mast cells in lesions of UP may have irregular shapes, sometimes with bilobated nuclei. On electron microscopy, they display a \"scroll poor\" phenotype with gratings and lattices. Other infiltrating cells may include eosinophils. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=see_link\">",
"     \"Mast cells: Development, identification, and physiologic roles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=see_link\">",
"     \"Mast cell derived mediators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It should be noted that mast cell numbers can be found increased in other inflammatory and neoplastic conditions of the skin such as dermatofibromas, psoriasis, atopic dermatitis, etc. However, these entities are also associated with additional characteristic pathologic changes in the skin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Systemic forms of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical markers of mast cell activation and biopsy findings of increased mast cell infiltration in bone marrow are common abnormalities in patients with systemic mastocytosis (SM). Abnormalities suggestive of organ dysfunction, such as liver and gastrointestinal disease, may also be seen among those with significant extracutaneous disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Serum tryptase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tryptase is a protease produced predominantly in mast cells, although a small amount is made by basophils and myeloid precursors as well. The presence of elevated serum concentrations of tryptase is one of the minor criteria for the diagnosis of mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Tryptase measurements are useful in distinguishing mastocytosis from mast cell activation (",
"    <a class=\"graphic graphic_table graphicRef79722 \" href=\"UTD.htm?37/24/38283\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Total tryptase",
"      </strong>",
"      - Total serum tryptase can be measured with a commercially available assay (ImmunoCAP tryptase",
"      <sup>",
"       &reg;",
"      </sup>",
"      , Phadia: Uppsala, Sweden), which is performed at many labs. Total tryptase is a measurement of both mature, active forms of tryptase, and immature, inactive forms (protryptases). Baseline tryptase is made up of immature (pro) tryptases that are constitutively secreted outside of the mast cell.",
"      <br/>",
"      <br/>",
"      Normal levels are between 1 and 11.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (some laboratories consider 15",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      to be the upper limit of normal) (",
"      <a class=\"graphic graphic_table graphicRef79722 \" href=\"UTD.htm?37/24/38283\">",
"       table 1",
"      </a>",
"      ). Systemic mastocytosis should be strongly suspected in patients with baseline levels of total tryptase greater than 20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      on at least two occasions [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Mature tryptase",
"      </strong>",
"      - Mature tryptase is stored in mast cell granules and is elevated in serum in mast cell activation. An assay for mature (beta-) tryptase is presently performed only at Virginia Commonwealth University (Richmond, Virginia) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/18\">",
"       18",
"      </a>",
"      ]. The serum level of mature tryptase in healthy blood donors is less than 1",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Levels of mature tryptase rise above 1",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      with mast cell activation and systemic anaphylaxis, reaching a peak approximately one hour after the event and generally returning to baseline after four hours. Mature tryptase levels are usually normal in patients with SM, unless they have just experienced an episode of massive mast cell activation. Measurement of mature tryptase is not required to make the diagnosis of mastocytosis, although it allows for an estimate of the total to mature ratio (",
"      <a class=\"graphic graphic_table graphicRef79722 \" href=\"UTD.htm?37/24/38283\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      <strong>",
"       Ratio of total to mature tryptase",
"      </strong>",
"      - If both measurements are available, the ratio of total to mature tryptase can be calculated. In healthy individuals without mastocytosis, the ratio is normally &lt;20 [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/19\">",
"       19",
"      </a>",
"      ]. In patients with systemic mastocytosis this ratio is &gt;20 (",
"      <a class=\"graphic graphic_table graphicRef79722 \" href=\"UTD.htm?37/24/38283\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During an acute anaphylactic event (in a patient without SM), mature tryptase rises and, if sufficiently high, can result in elevations of total tryptase. Mature tryptase levels &gt;1",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    total tryptase levels &gt;11",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and a ratio of total to mature of &lt;10 are each consistent with systemic anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef79722 \" href=\"UTD.htm?37/24/38283\">",
"     table 1",
"    </a>",
"    ). The interpretation of tryptase levels in patients with suspected anaphylaxis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=see_link\">",
"     \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The absolute level of total tryptase does",
"    <strong>",
"     not",
"    </strong>",
"    predict the category of mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/19\">",
"     19",
"    </a>",
"    ]. Aggressive mastocytosis and mastocytosis associated with hematological malignancies can have similar elevations of tryptase as ISM. However, MCL is generally associated with extremely elevated tryptase levels, sometimes up to range of &gt;1000",
"    <span class=\"nowrap\">",
"     ng/ml.",
"    </span>",
"    In general, there is a good correlation between an elevated total tryptase level and a positive bone marrow biopsy.",
"   </p>",
"   <p>",
"    Tryptase elevations can also be detected in conditions other than mastocytosis, including patients with myeloproliferative or myelodysplastic disease, chronic renal or liver failure, and chronic eosinophilic leukemia. Persistently high tryptase was reported in one individual with no other criteria for mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/20\">",
"     20",
"    </a>",
"    ]. This was attributed to the presence of human anti-mouse antibodies that interfered with the immunoassay used to detect tryptase, which utilizes mouse monoclonal antibodies. Human anti-animal antibodies can be found in people who have received mouse monoclonal antibodies for imaging and therapeutic purposes, have occupational (farm or laboratory) or domestic animal exposure, or ingest cow's milk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Another report described a significant association between the presence of IgM rheumatoid factor and heterophilic antibodies interfering with tryptase immunoassay, also resulting in falsely elevated tryptase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Urinary histamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The measurement of histamine or its metabolites in a 24 hour urine collection has been used in the diagnosis of systemic mastocytosis, particularly prior to the availability of tryptase measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/24\">",
"     24",
"    </a>",
"    ]. Levels of urinary histamine are elevated in adults with systemic mastocytosis. A urinary histamine concentration of up to 30",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is considered normal, although laboratories may utilize different units. Levels of urinary histamine can be found elevated in adults with systemic mastocytosis.",
"   </p>",
"   <p>",
"    Urinary histamine measurements can be affected by diet and urinary tract flora. Urinary histamine metabolites such as N-methylhistamine provide a more accurate assessment, but are neither more sensitive nor specific than serum tryptase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, increased histamine metabolite levels in urine obtained during a symptomatic episode, such as flushing or syncope, does not distinguish between anaphylaxis and systemic mastocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bone marrow findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In healthy individuals, bone marrow mast cells represent less than 1 percent of all nucleated cells and have a morphology similar to mature mast cells in normal tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/26\">",
"     26",
"    </a>",
"    ]. Normal bone marrow mast cells are round cells with small nuclei and granulated cytoplasm that stains with metachromatic dyes. Protease stains indicate that these cells are of the MCtc phenotype, expressing tryptase and chymase and carboxypeptidase A3 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bone marrow in patients with systemic mastocytosis ranges from normocellular to markedly hypercellular [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The clinical significance of the marrow burden of mast cells is unclear, but advanced forms of disease such as aggressive systemic mastocytosis and mast cell leukemia are associated with extensive bone marrow infiltration.",
"   </p>",
"   <p>",
"    Among those with SM, frequently observed atypical mast cells have a spindle or fusiform shape, oval nuclei that are eccentric, hypogranular cytoplasm with focal accumulation of granules with or without granule fusion, and a high ratio nucleus:cytoplasm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/28\">",
"     28",
"    </a>",
"    ]. Multifocal aggregates of such spindle shaped mast cells that contain at least 15 mast cells per aggregate are diagnostic for systemic mastocytosis. Smaller aggregates with round mast cells of normal morphology as well as diffuse increases can also be found (",
"    <a class=\"graphic graphic_figure graphicRef78615 \" href=\"UTD.htm?19/36/20038\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef69849 \" href=\"UTD.htm?11/34/11813\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The typical phenotype in systemic mastocytosis is a mastocytosis positive for CD117, CD25, tryptase, and chymase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/30\">",
"     30",
"    </a>",
"    ]. Localization is predominantly paratrabecular and perivascular with thickened bony trabeculae, although interstitial infiltrates are not uncommon. Bone marrow mast cells can be very immature and hypogranulated and only recognizable by specific tryptase staining, rather than metachromatic stains such as Giemsa or toluidine blue. Morphologically immature (multilobated or clefted nuclei, hypogranulated) bone marrow mast cells comprising more than 20 percent of cells in a non-spicular area of the bone marrow smear is diagnostic for mast cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/28,31\">",
"     28,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone marrow blood, collected at the time of bone marrow biopsy, may show elevated tryptase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/15\">",
"     15",
"    </a>",
"    ]. This was reported in one small study of seven patients, although the technique requires further validation, and its diagnostic utility has not been verified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Histologic evaluation of additional organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic evaluation of organs other than bone marrow is generally not recommended for diagnosis of systemic mastocytosis as bone marrow is almost always involved and the pathologic significance of increased mast cells in other tissues have not been carefully studied. Interpretation of gastrointestinal tract biopsies is problematic because mast cells are normally abundant in these tissues and so additional increases in normal mast cell concentration or the presence of aggregates are difficult to appreciate [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exceptions to this include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a minority of cases, extracutaneous and extramedullary organs are examined because of enlargement or dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/33\">",
"       33",
"      </a>",
"      ]. Multifocal aggregates of spindle shaped mast cells can be found that are similar to those in the bone marrow.",
"     </li>",
"     <li>",
"      Staining of the gastrointestinal mast cells for CD25 may be helpful when bone marrow sampling is not possible [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     KIT mutational analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with systemic mastocytosis should undergo a mutational analysis of KIT, particularly for the presence of Asp816Val mutation. This analysis can be performed on peripheral white blood cells, bone marrow, or cells from other extracutaneous organs. However, bone marrow lesional tissue yields the most sensitive results. Analysis of the peripheral blood is the least sensitive, as the mutation generally becomes detectable in peripheral blood in advanced forms of disease with multilineage involvement.",
"   </p>",
"   <p>",
"    When appropriate tissues are analyzed, the D816V c-kit mutation is identified in more than 90 percent of patients with systemic mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition to diagnostic information, this may aid in determining therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Flow cytometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cells from patients with systemic mastocytosis express the surface markers, CD2 (LFA-2) and CD25 (IL-2 receptor alpha chain), distinguishing them from normal or reactive mast cells, which display neither marker [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4,36\">",
"     4,36",
"    </a>",
"    ]. The expression of one or both of these markers is a minor criterion for the diagnosis (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Diagnosis'",
"    </a>",
"    below). Mast cells can be identified in bone marrow aspirates as a CD117 high, IgE+ population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/3,36,37\">",
"     3,36,37",
"    </a>",
"    ]. In cases where bone marrow aspirate is not available for flow cytometry, immunohistochemical staining for CD25 may be performed in serial core biopsy sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional abnormalities may be as detected by radiography, CT scan, magnetic resonance imaging, bone scan, gastrointestinal studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endoscopy, depending upon the extent of organ infiltration and the symptoms of the patient.",
"   </p>",
"   <p>",
"    The diagnosis of clonal mast cell disorders based on biopsies other than bone marrow should generally be avoided.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Gastrointestinal biopsies",
"      </strong>",
"      - Increased mast cell numbers can be found in gastrointestinal tract biopsies from patients with inflammatory bowel diseases and bacterial and parasitic infections, as well as in some patients with systemic mast cell disease. There are conflicting reports about the gastrointestinal mast cell density in patients with systemic mastocytosis. One study found greater than 20 mast cells per high power field in a subset of patients with chronic intractable diarrhea without evidence of mastocytosis or other inflammatory bowel disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/38\">",
"       38",
"      </a>",
"      ]. These patients were termed as having mastocytic enterocolitis. These findings need to be verified in future studies. Another study found decreased numbers of mast cells in gastric and duodenal biopsies of patients with systemic mastocytosis when compared to controls [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/32\">",
"       32",
"      </a>",
"      ], while other studies reported increased numbers [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/36\">",
"       36",
"      </a>",
"      ]. Thus, increased mast cell numbers in gastrointestinal biopsies should not be interpreted as diagnostic of a systemic mast cell disease. Patients with gastrointestinal symptoms are sometimes inappropriately diagnosed with either systemic mastocytosis or \"mast cell activation syndrome\" based upon gastrointestinal biopsies. However, expression of CD25 in gastrointestinal mast cells is a useful diagnostic marker for presence of systemic mastocytosis.",
"     </li>",
"     <li>",
"      <strong>",
"       Bladder wall biopsies",
"      </strong>",
"      - Patients with the diagnosis of \"mast cell activation syndrome\" sometimes have a variety of waxing and waning symptoms affecting multiple systems. Symptoms similar to interstitial cystitis may be observed in some patients. Increased numbers of degranulated mast cells in bladder biopsies suggest that mast cells contribute to some of the pathology of this disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/39\">",
"       39",
"      </a>",
"      ]. However, a diagnosis of interstitial cystitis does not generally raise suspicion for the presence of systemic mastocytosis. In some patients, improvement of symptoms with drugs targeting mast cell mediators (such as H1 and H2 antihistamines, cromolyn, leukotriene antagonists) are considered as further supporting evidence of mast cell involvement in disease process. However, these findings are nonspecific and do not support the diagnosis of a primary systemic mast cell disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cutaneous mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of cutaneous mastocytosis is based upon the presence of suggestive signs and symptoms, combined with characteristic cutaneous lesions and findings on skin biopsy (",
"    <a class=\"graphic graphic_table graphicRef82827 \" href=\"UTD.htm?10/20/10572\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Skin biopsy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the World Health Organization's (WHO) diagnostic criteria, the definitive diagnosis of systemic mastocytosis requires either the presence of one major and one minor criteria",
"    <strong>",
"     OR",
"    </strong>",
"    three minor criteria (",
"    <a class=\"graphic graphic_table graphicRef82827 \" href=\"UTD.htm?10/20/10572\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Major criterion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major criterion is the presence in bone marrow or other extracutaneous organs of multifocal dense aggregates of greater than 15 mast cells as detected with tryptase or other special stains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Minor criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four minor criteria have been defined:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical morphology or spindle shapes in &gt;25 percent of the mast cells in bone marrow sections, bone marrow aspirate, or other extracutaneous tissues.",
"     </li>",
"     <li>",
"      Mutational analysis of KIT showing a codon 816 mutation (eg, Asp816Val) in bone marrow, blood, or extracutaneous organs.",
"     </li>",
"     <li>",
"      Bone marrow or other extracutaneous mast cells expressing the surface markers CD2, CD25, or both.",
"     </li>",
"     <li>",
"      Serum tryptase levels (when the patient is in a baseline state) &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Values &gt;11.4",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      are considered elevated in most diagnostic laboratories; however, the WHO criterion is currently defined as a value &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Of note, the serum tryptase criterion does not apply to patients with an associated hematologic clonal non-mast cell lineage disease (AHNMD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bone marrow biopsy is the optimal means of pursuing the diagnosis of systemic mastocytosis. Other organs (such as spleen or lymph nodes) are occasionally used as a source of mast cells if they have been removed as part of evaluation or treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis can be confused either clinically or histologically with a variety of disorders, although application of WHO criteria to pathologic samples confirms or rules out the diagnosis of systemic mastocytosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Disorders with similar clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis is a histopathologic diagnosis and should not be based solely on clinical presentation. The ability to distinguish SM from illnesses with similar clinical manifestations is principally based upon the presence or absence of elevated levels of biochemical mediators of mast cell activation, including tryptase and histamine, the lack of skin lesions typical for systemic mastocytosis, and a definitive histologic diagnosis of SM:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Monoclonal mast cell activation syndrome",
"      </strong>",
"      &mdash; The term monoclonal mast cell activation syndrome (MMAS) has been accepted by a consensus panel as appropriate for patients who experience episodes of mast cell activation symptoms such as recurrent flushing, gastrointestinal cramping, and hypotension and meet one or two of the minor diagnostic criteria for systemic mastocytosis (eg, c-kit D816V or aberrant CD25 expression on mast cells), but do not fully meet diagnostic criteria for systemic mastocytosis. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Minor criteria'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Patients with MMAS may present with hypotensive reactions to Hymenoptera stings and demonstrate baseline serum tryptase values that are normal or mildly increased. Bone marrow findings do not meet criteria for systemic mastocytosis, although some cells express the aberrant markers CD2 and CD25",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      KIT mutations. MMAS is reviewed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"       \"Mast cell activation disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Anaphylaxis",
"      </strong>",
"      &mdash; Clinical criteria for the diagnosis of anaphylaxis have been defined (",
"      <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"       table 3",
"      </a>",
"      ). Patients with anaphylaxis may have elevations of serum beta (mature) tryptase during (or for several hours after) acute events. In contrast, patients with systemic mastocytosis have persistent elevations in total tryptase in the baseline state. Patients with hymenoptera anaphylaxis and elevated random tryptase should be evaluated for systemic mastocytosis, regardless of the results of testing for hymenoptera sensitization. Idiopathic anaphylaxis is a diagnosis of exclusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=see_link\">",
"       \"Idiopathic anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Mast cell activation syndrome",
"      </strong>",
"      &mdash; Mast cell activation syndrome (MCAS) is a term proposed to describe an idiopathic disorder in which patients present with recurrent episodes of signs and symptoms that are consistent with mast cell activation and affect at least two organ systems (ie, cutaneous, gastrointestinal, cardiovascular, respiratory, or naso-ocular) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/40\">",
"       40",
"      </a>",
"      ]. Of note, the signs and symptoms should",
"      <strong>",
"       not",
"      </strong>",
"      fulfill criteria for anaphylaxis (",
"      <a class=\"graphic graphic_table graphicRef72225 \" href=\"UTD.htm?22/43/23228\">",
"       table 3",
"      </a>",
"      ), nor should there be any KIT mutations or mast cell CD25 expression. If the criteria for anaphylaxis are met, then the diagnosis of idiopathic anaphylaxis is more appropriate.",
"      <br/>",
"      <br/>",
"      In addition, elevations in mast cell mediators in serum or urine should be documented as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients with a baseline serum total tryptase &ge;15",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      a further increase in serum tryptase, 24 hour urine N-methylhistamine or prostaglandin D",
"      <sub>",
"       2",
"      </sub>",
"      or its metabolite 11-&beta;-prostaglandin F",
"      <sub>",
"       2",
"      </sub>",
"      should be demonstrated on at least",
"      <strong>",
"       one",
"      </strong>",
"      occasion during a symptomatic period.",
"     </li>",
"     <li>",
"      In patients with a baseline serum tryptase &lt;15",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      an increase in the same mediators should be demonstrated on at least",
"      <strong>",
"       two",
"      </strong>",
"      occasions during symptomatic periods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Finally, patients should exhibit a favorable clinical response to medications that counteract mast cell mediators, including H1 and H2 antihistamines, antileukotriene medications or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The clinical and laboratory findings of systemic mastocytosis (SM), MMAS, MCAS, and idiopathic anaphylaxis (IA) are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef74223 \" href=\"UTD.htm?33/15/34044\">",
"     table 4",
"    </a>",
"    ). MCAS is reviewed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=see_link\">",
"     \"Mast cell activation disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The next group of disorders described below, which can have some clinical features similar to mastocytosis, do not involve mast cell activation. Therefore, serum tryptase and urinary histamine are not elevated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Hereditary/acquired",
"       </strong>",
"      </span>",
"      angioedema",
"      - Patients with hereditary or acquired angioedema due to deficiency of C1 inhibitor present with episodes of angioedema (generally painful) affecting the skin, larynx,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      walls of the bowel. In contrast, laryngeal edema is unusual in mastocytosis, and C1 inhibitor and complement studies are typically within normal range in mastocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=see_link\">",
"       \"An overview of angioedema: Clinical features, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Carcinoid syndrome",
"      </strong>",
"      - The presence of episodic flushing and diarrhea may raise suspicion for mastocytosis among patients with the carcinoid syndrome. Elevations of 24 hour urine 5-HIAA are indicative of carcinoid syndrome, whereas this mediator is normal in mastocytosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pheochromocytoma",
"      </strong>",
"      - Patients with pheochromocytoma may present with flushing and paroxysmal episodes of hypertension, whereas patients with mastocytosis generally develop hypotension during an acute mast cell degranulation episode. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"       \"Clinical presentation and diagnosis of pheochromocytoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Metastatic disease to bone",
"      </strong>",
"      - Bone lesions of systemic mastocytosis are frequently misinterpreted radiographically as metastatic lesions to bone; however, elevated serum tryptase and urinary histamine are absent with malignancy. Thus, histopathologic diagnosis is required to differentiate between these two disorders.",
"     </li>",
"     <li>",
"      <strong>",
"       Vasoactive intestinal peptide-secreting tumors",
"      </strong>",
"      - Symptoms found in both systemic mastocytosis and vasoactive intestinal peptide secreting tumors include flushing episodes and particularly diarrhea. Vasoactive intestinal peptide (VIP)-secreting tumors are associated with increased levels of VIP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"       \"The VIPoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Zollinger-Ellison syndrome",
"      </strong>",
"      - A significant number of patients with the Zollinger-Ellison syndrome present with diarrhea. Some affected individuals may also have metastatic disease to bone. However, Zollinger-Ellison syndrome is not associated with elevated levels of histamine or tryptase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Disorders with similar bone marrow manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few disorders have increased",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aberrantly shaped mast cells similar to findings in the bone marrow as observed in patients with SM. These are principally chronic eosinophilic leukemia, primary myelofibrosis, and reactive mastocytosis, which are distinguished from mastocytosis by differences on bone marrow biopsy as well as the presence or absence of characteristic clinical and laboratory features.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chronic eosinophilic leukemia or myeloproliferative variant of hypereosinophilic syndrome",
"      </strong>",
"      - These disorders are characterized by a modest elevation in serum tryptase and atypical spindle shaped mast cells expressing surface CD25. However, molecular diagnostic studies reveal the presence of FIP1L1-PDGFRA fusion instead of a D816V KIT mutation. The typical patient is a male without urticaria pigmentosa and a hypercellular (myeloproliferative) bone marrow with elevated serum vitamin B12 levels. This is a stem cell disorder affecting multiple hematopoietic lineages including the mast cell, but the clinical disease manifestations are due to eosinophil-related pathology rather than increased mast cells. Some patients may meet the diagnostic criteria of both disorders (systemic mastocytosis associated with CEL). These patients respond well to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"       imatinib",
"      </a>",
"      , whereas patients with typical mastocytosis and D816V c-kit mutations do not. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=see_link\">",
"       \"Treatment of the hypereosinophilic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Primary myelofibrosis",
"      </strong>",
"      - Bone marrow biopsy in patients with primary myelofibrosis typically reveals extensive fibrosis, which may be accompanied by spindle shaped mast cells, a finding that can also be observed with mastocytosis in the setting of extensive mast cell infiltration. However, mast cell increase is usually diffuse and interstitial rather than forming clusters. Also, mast cells in myelofibrosis lack pathologic CD25 expression and c-kit D816V mutation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=see_link\">",
"       \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Reactive mastocytosis",
"      </strong>",
"      - Reactive mastocytosis in tissues and bone marrow can be seen in patients with solid tumors, such as breast cancer, Hodgkin lymphoma, and in diseases variably associated with increased expression of stem cell factor (eg, aplastic anemia and some hematologic, soft tissue and gastrointestinal neoplasms). Reactive mast cells generally have a mature appearance (round in shape and fully granulated) and lack significant clustering and aberrant surface expression of CD2 and CD25 or KIT mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     DETERMINING THE CATEGORY OF SYSTEMIC MASTOCYTOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of systemic mastocytosis has been made, the category of SM should be determined. Each category is distinguished by various features (",
"    <a class=\"graphic graphic_table graphicRef82828 \" href=\"UTD.htm?12/42/12973\">",
"     table 5",
"    </a>",
"    ). To establish the category of SM present, a bone marrow biopsy, serum tryptase levels, complete blood counts with differential, and liver function tests are recommended for all patients. Depending on the clinical presentation, the following additional studies may be indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Coagulation studies (PT, PTT)",
"     </li>",
"     <li>",
"      Gastrointestinal endoscopy with biopsies",
"     </li>",
"     <li>",
"      Bone radiography to evaluate bone pain and assess for pathologic fractures",
"     </li>",
"     <li>",
"      Total body radionuclide bone scan",
"     </li>",
"     <li>",
"      Bone densitometry to evaluate for bone loss, since mastocytosis is a risk factor for osteoporosis",
"     </li>",
"     <li>",
"      Abdominal ultrasonography or CT scan to evaluate for splenomegaly, hepatomegaly, and lymphadenopathy",
"     </li>",
"     <li>",
"      KIT mutational analysis (generally performed at the time of bone marrow biopsy, and preferably on bone marrow aspirate cells)",
"     </li>",
"     <li>",
"      Cytogenetic analysis in patients with suspected co-existent hematologic disease",
"     </li>",
"     <li>",
"      FISH for CHIC2 deletion in patients with suspected co-existent chronic eosinophilic",
"      <span class=\"nowrap\">",
"       leukemia/myeloproliferative",
"      </span>",
"      HES (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the presence of B and C findings should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     B findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;B findings refer to organ enlargement without organ dysfunction and may be observed in patients with indolent systemic mastocytosis with high mast cell burden. Patients with smoldering ISM have a high mast cell burden and extensive bone marrow infiltration by mast cells, but no features of aggressive disease or an associated hematologic non-mast cell clonal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4\">",
"     4",
"    </a>",
"    ]. B-findings include the following (",
"    <a class=\"graphic graphic_table graphicRef82828 \" href=\"UTD.htm?12/42/12973\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltration of bone marrow such that mast cells comprise &gt;30 percent of cells and serum tryptase is &gt;200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      Hypercellular bone marrow with loss of fat cells or discrete signs of myelodysplasia or myeloproliferation (but insufficient to diagnose MDS or MPD), normal blood counts, or slight persisting deviation without progression",
"     </li>",
"     <li>",
"      Palpable hepatomegaly without ascites or other signs of organ impairment",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palpable lymphadenopathy or visceral node enlargement (&lt;2 cm) found on ultrasound or CT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      palpable splenomegaly without hypersplenism",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     C findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;C findings denote organ-function impairment due to excessive mast cell infiltration and are associated with aggressive disease and a poorer prognosis. C findings are present in aggressive systemic mastocytosis. In addition, they may be observed in mast cell leukemia. C findings include (",
"    <a class=\"graphic graphic_table graphicRef82828 \" href=\"UTD.htm?12/42/12973\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytopenias due to bone marrow infiltration, as defined by one or more of the following: absolute neutrophil count &lt;1000",
"      <span class=\"nowrap\">",
"       cells/mcL,",
"      </span>",
"      hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      platelets &lt;100,000 mcL [",
"      <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/42\">",
"       42",
"      </a>",
"      ]. In patients with SM-AHNMD, it may be difficult to determine whether the cytopenias are due to mastocytosis or the associated hematologic disorder.",
"     </li>",
"     <li>",
"      Palpable hepatomegaly with ascites, elevated liver function tests (eg, hepatic enzymes, alkaline phosphatase, and LDH), impaired synthesis of albumin and coagulation factors,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      portal hypertension.",
"     </li>",
"     <li>",
"      Palpable splenomegaly with hypersplenism (ie, nonimmune hemolytic anemia and other hematologic abnormalities) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Malabsorption due to mast cell infiltration of the intestinal tract, with hypoalbuminemia and weight loss (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=see_link\">",
"       \"Clinical features and diagnosis of malabsorption\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Bone lesions with large osteolyses",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severe osteoporosis with spontaneous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pathologic fractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Indolent systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with indolent systemic mastocytosis (ISM) are adults or children over 10 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4,43\">",
"     4,43",
"    </a>",
"    ]. ISM is the most prevalent form of systemic mastocytosis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. In the majority of cases of ISM, UP lesions are present, and the diagnosis is made by histologic examination of the skin and bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/46\">",
"     46",
"    </a>",
"    ]. The KIT mutation Asp816Val is detected in skin lesions and bone marrow mast cells, and rarely in peripheral blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of B findings defines the \"smoldering\" subtype of ISM [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/4\">",
"     4",
"    </a>",
"    ]. Although mast cell infiltrates can be detected in various organs (including liver, spleen, and gastrointestinal tract), the clinical course is generally indolent. However, these patients should be followed for progression to a more aggressive form of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SM-AHNMD fulfill clinical criteria for systemic mastocytosis and another hematologic syndrome or neoplasia according to WHO criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/43,48\">",
"     43,48",
"    </a>",
"    ]. Associated neoplastic processes include myelodysplastic syndromes, chronic myeloproliferative disorders, acute myeloid leukemia (especially core binding factor leukemias associated with cytogenetic abnormalities t8;21 and inv 16), chronic eosinophilic leukemia, and less commonly, lymphoproliferative disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=see_link\">",
"     \"Overview of the myeloproliferative neoplasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike those with ISM, only 50 percent of patients with SM-AHNMD have UP-like skin lesions. As a result, the diagnosis of mastocytosis may be missed or delayed. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Differential diagnosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Aggressive systemic mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggressive systemic mastocytosis (ASM), a clinically severe form of systemic mastocytosis, occurs in a minority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/33\">",
"     33",
"    </a>",
"    ]. This category of SM is characterized by one or more C findings (ie, organ-function impairment due to excessive mast cell mass) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'C findings'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    UP lesions can be present or absent. Mast cells in the bone marrow biopsy typically occupy &gt;20 percent of the marrow space but are typically",
"    <strong>",
"     less than 20 percent",
"    </strong>",
"    of nucleated cells in the aspirate smear, which distinguishes ASM from mast cell leukemia. Signs of dysplasia and myeloproliferation can be found, but do",
"    <strong>",
"     not",
"    </strong>",
"    fulfill criteria for hematologic malignancy.",
"   </p>",
"   <p>",
"    Tryptase levels are invariably increased. Mutations of c-kit kinase domain may be present, including the most common Asp816Val mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variant of ASM can also present with lymphadenopathic mastocytosis with blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Mast cell leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell leukemia (MCL) is the rarest and most aggressive category of systemic mastocytosis. It is characterized by more than 10 percent circulating mast cells in peripheral blood or more than 20 percent mast cells in the bone marrow aspirate with atypical features. In the bone marrow, cells can be very immature and hypogranulated with blast-like morphology and high nucleus:cytoplasm ratios, and may contain mitotic figures. For the purpose of diagnosing MCL, the percentage of mast cells should be determined in a non-spicular part of the bone marrow aspirate smear and not in bone marrow biopsy sections.",
"   </p>",
"   <p>",
"    Mast cells are not found in peripheral blood in healthy individuals and in patients with indolent systemic mastocytosis. Therefore, the number of circulating mast cells in the peripheral blood may help distinguish MCL from other categories of mastocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The number of circulating mast cells in MCL can vary considerably. As an example, an \"aleukemic\" variant of MCL is characterized by less than 10 percent circulating mast cells in the presence of &gt;20 percent immature mast cells in bone marrow aspirate smears.",
"   </p>",
"   <p>",
"    Typically, although UP lesions are absent, initial clinical presentation of the disease cannot be distinguished from the other categories. Signs and symptoms include flushing, hypotension, and diarrhea. Plasma tryptase levels are usually extremely high. Mutations of the activation domain of KIT at codon 816 can be observed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/53\">",
"     53",
"    </a>",
"    ]. This mutation was originally described in the HMC-1 cell line derived from a patient who died of mast cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progression to multiple organ failure with weight loss, bone pain, and organomegaly develops over months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     MAST CELL SARCOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mast cell sarcoma is a rare disorder, with few well documented cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. Subsequent evolution to mast cell leukemia may occur. The sarcoma is a locally destructive lesion without systemic (bone marrow) involvement at the time of the diagnosis. Atypical sarcomatous mast cells have been reported within the larynx, colon, brain, skin, and mucosal tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     EXTRACUTANEOUS MASTOCYTOMAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracutaneous mastocytomas are also rare, and are characterized by accumulation of mature mast cells in an organ other than the skin, without aggressive features. Most reported cases were localized to the lung. In a report of a skull mastocytoma, significant bone destruction was induced by the mast cell mass [",
"    <a class=\"abstract\" href=\"UTD.htm?18/13/18650/abstract/57\">",
"     57",
"    </a>",
"    ]. Evolution of extracutaneous mastocytomas to mast cell sarcoma has not been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mastocytosis is a group of disorders caused by excessive mast cell proliferation. Mastocytosis limited to the skin is called cutaneous mastocytosis, whereas mastocytosis involving extracutaneous tissues is called systemic mastocytosis. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation of a patient with suspected mastocytosis (cutaneous or systemic) begins by evaluation for signs and symptoms of systemic involvement, and a skin examination for suspicious lesions, such as urticaria pigmentosa, a fixed and diffuse dermatitis composed of small, fixed, hyperpigmented macules that urticate or flush when rubbed (Darier's sign) (",
"      <a class=\"graphic graphic_picture graphicRef63025 \" href=\"UTD.htm?40/49/41746\">",
"       picture 1",
"      </a>",
"      ). In addition, a complete blood count with differential, liver function tests, and a serum tryptase should be obtained. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with lesions consistent with cutaneous mastocytosis should undergo a punch biopsy of skin lesions with specific histopathologic stains, if there is any doubt about the diagnosis. Skin biopsy findings in the context of the morphologic lesion are diagnostic of cutaneous mastocytosis, but do not provide information about systemic involvement. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Skin biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone marrow biopsy is not routinely performed in infants and children with cutaneous mastocytosis, unless there are specific findings to suggest other organ involvement (eg, unexplained abnormalities on the CBC, hepatomegaly, splenomegaly, or lymphadenopathy). In contrast, adult patients with urticaria pigmentosa, an elevated serum tryptase level, or signs and symptoms of systemic involvement should undergo bone marrow biopsy and aspiration. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications for bone marrow examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In cutaneous mastocytosis, laboratories are typically normal and the diagnosis is confirmed by skin biopsy findings (",
"      <a class=\"graphic graphic_table graphicRef82827 \" href=\"UTD.htm?10/20/10572\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cutaneous forms of disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Cutaneous mastocytosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In systemic mastocytosis, abnormalities include characteristic bone marrow findings, a persistently elevated baseline total tryptase (&gt;20",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      (",
"      <a class=\"graphic graphic_table graphicRef79722 \" href=\"UTD.htm?37/24/38283\">",
"       table 1",
"      </a>",
"      ), and variable other findings of systemic involvement. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic forms of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of systemic mastocytosis requires either the presence of the major criterion and one of the minor criteria, OR three of the minor criteria (in the absence of the major criterion) (",
"      <a class=\"graphic graphic_table graphicRef82827 \" href=\"UTD.htm?10/20/10572\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the diagnosis of systemic mastocytosis has been established, further evaluation is performed to determine which of the categories of disease is present and whether there are B or C findings present (",
"      <a class=\"graphic graphic_table graphicRef82828 \" href=\"UTD.htm?12/42/12973\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Determining the category of systemic mastocytosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Some centers with extensive experience in the United States include Brigham and Women's Hospital, the National Institutes of Health (NIH), Mayo Clinic, and MD Anderson Cancer Center.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/2\">",
"      Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/3\">",
"      Akin C, Valent P, Escribano L. Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. Curr Allergy Asthma Rep 2006; 6:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/4\">",
"      Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol 2004; 114:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/5\">",
"      Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med 2004; 55:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/6\">",
"      Hartmann K, Metcalfe DD. Pediatric mastocytosis. Hematol Oncol Clin North Am 2000; 14:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/7\">",
"      Akin C, Scott LM, Kocabas CN, et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis. Blood 2007; 110:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/8\">",
"      Gonz&aacute;lez de Olano D, de la Hoz Caballer B, N&uacute;&ntilde;ez L&oacute;pez R, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/9\">",
"      Sheridan RL, Liu V, Anupindi S. Case records of the Massachusetts General Hospital. Case 34-2005. A 10-year-old girl with a bullous skin eruption and acute respiratory failure. N Engl J Med 2005; 353:2057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/10\">",
"      Walker T, von Komorowski G, Scheurlen W, et al. Neonatal mastocytosis with pachydermic bullous skin without c-Kit 816 mutation. Dermatology 2006; 212:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/11\">",
"      Murphy M, Walsh D, Drumm B, Watson R. Bullous mastocytosis: a fatal outcome. Pediatr Dermatol 1999; 16:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/12\">",
"      Travis WD, Li CY, Bergstralh EJ, et al. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 1988; 67:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/13\">",
"      Soter NA. Mastocytosis and the skin. Hematol Oncol Clin North Am 2000; 14:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/14\">",
"      Wolff K, Komar M, Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/15\">",
"      Proelss J, Wenzel J, Ko Y, et al. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis. J Am Acad Dermatol 2007; 56:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/16\">",
"      Schwartz LB, Metcalfe DD, Miller JS, et al. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/17\">",
"      Schwartz LB, Irani AM. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:641.",
"     </a>",
"    </li>",
"    <li>",
"     The laboratory can be contacted at (804) 828-9685.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/19\">",
"      Schwartz LB, Sakai K, Bradford TR, et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995; 96:2702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/20\">",
"      van Toorenenbergen AW, van Daele PL, Boonstra JG. False-elevated serum tryptase assay result caused by heterophilic antibodies. J Allergy Clin Immunol 2005; 116:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/21\">",
"      Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/22\">",
"      Andersen DC, Koch C, Jensen CH, et al. High prevalence of human anti-bovine IgG antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies. J Immunoassay Immunochem 2004; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/23\">",
"      van Toorenenbergen AW, Hooijkaas H, Heerenbrink GK, Dufour-van den Goorbergh DM. Heterophilic antibody interference in a tryptase immunoassay. Clin Biochem 2008; 41:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/24\">",
"      Granerus G, Olafsson JH, Roupe G. Studies on histamine metabolism in mastocytosis. J Invest Dermatol 1983; 80:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/25\">",
"      Akin C, Metcalfe DD. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 2002; 127:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/26\">",
"      Irani AM, Bradford TR, Kepley CL, et al. Detection of MCT and MCTC types of human mast cells by immunohistochemistry using new monoclonal anti-tryptase and anti-chymase antibodies. J Histochem Cytochem 1989; 37:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/27\">",
"      Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract 1993; 189:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/28\">",
"      Parker RI. Hematologic aspects of systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/29\">",
"      Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol 1985; 16:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/30\">",
"      Parker RI. Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease. J Invest Dermatol 1991; 96:47S.",
"     </a>",
"    </li>",
"    <li>",
"     Horny HP, Metcalf DD, Bennett JM, et al. Mastocytosis. In: WHO classification of tumors of hematopoietic and lymphoid tissues., Swerdlow SH, Campo E, Harris NL, et al.  (Eds), Lyon IARC Press, Lyon 2008. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/32\">",
"      Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000; 14:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/33\">",
"      Castells MC, Friend DS, Bunnell CA, et al. The presence of membrane-bound stem cell factor on highly immature nonmetachromatic mast cells in the peripheral blood of a patient with aggressive systemic mastocytosis. J Allergy Clin Immunol 1996; 98:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/34\">",
"      Hahn HP, Hornick JL. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007; 31:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/35\">",
"      Akin C. Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/36\">",
"      Escribano L, Orfao A, D&iacute;az-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998; 91:2731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/37\">",
"      Escribano L, D&iacute;az-Agust&iacute;n B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001; 25:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/38\">",
"      Jakate S, Demeo M, John R, et al. Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med 2006; 130:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/39\">",
"      Sant GR, Kempuraj D, Marchand JE, Theoharides TC. The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis. Urology 2007; 69:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/40\">",
"      Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/41\">",
"      Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/42\">",
"      Lawrence JB, Friedman BS, Travis WD, et al. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am J Med 1991; 91:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/43\">",
"      Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991; 96:2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/44\">",
"      Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991; 96:5S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/45\">",
"      Escribano L, Akin C, Castells M, et al. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002; 81:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/46\">",
"      Topar G, Staudacher C, Geisen F, et al. Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults. Am J Clin Pathol 1998; 109:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/47\">",
"      Longley BJ, Metcalfe DD. A proposed classification of mastocytosis incorporating molecular genetics. Hematol Oncol Clin North Am 2000; 14:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/48\">",
"      Horny HP, Sotlar K, Sperr WR, Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/49\">",
"      Reisberg IR, Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am J Gastroenterol 1987; 82:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/50\">",
"      Floman Y, Amir G. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. J Spinal Disord 1991; 4:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/51\">",
"      Torrey E, Simpson K, Wilbur S, et al. Malignant mastocytosis with circulating mast cells. Am J Hematol 1990; 34:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/52\">",
"      Travis WD, Li CY, Hoagland HC, et al. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986; 61:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/53\">",
"      Huang TY, Yam LT, Li CY. Radiological features of systemic mast-cell disease. Br J Radiol 1987; 60:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/54\">",
"      Furitsu T, Tsujimura T, Tono T, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/55\">",
"      Horny HP, Parwaresch MR, Kaiserling E, et al. Mast cell sarcoma of the larynx. J Clin Pathol 1986; 39:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/56\">",
"      Kojima M, Nakamura S, Itoh H, et al. Mast cell sarcoma with tissue eosinophilia arising in the ascending colon. Mod Pathol 1999; 12:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/13/18650/abstract/57\">",
"      Castells MC. Extracutaneous mastocytoma. J Allergy Clin Immunol 2006; 117:1513.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4784 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-2BDF7BB03E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18650=[""].join("\n");
var outline_f18_13_18650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL APPROACH TO THE PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3577287\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Laboratories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19185617\">",
"      When to refer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications for bone marrow examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bone marrow studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Evaluation of common presentations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Urticaria pigmentosa in a child",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19185637\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Urticaria pigmentosa in an adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Symptoms related to mast cell mediators, without skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3581667\">",
"      Unexplained severe allergic or anaphylactic reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cutaneous forms of disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Laboratory results",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Histopathology of skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Systemic forms of disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Serum tryptase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Urinary histamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bone marrow findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Histologic evaluation of additional organs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - KIT mutational analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Flow cytometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cutaneous mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Major criterion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Minor criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Disorders with similar clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Disorders with similar bone marrow manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      DETERMINING THE CATEGORY OF SYSTEMIC MASTOCYTOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      B findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      C findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Indolent systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Systemic mastocytosis with associated clonal hematologic non-mast cell lineage disorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Aggressive systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Mast cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      MAST CELL SARCOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      EXTRACUTANEOUS MASTOCYTOMAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/4784\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4784|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/36/20038\" title=\"figure 1\">",
"      Sys masto BM stained for tryptase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4784|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/49/41746\" title=\"picture 1\">",
"      Urticaria pigmentosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/50/30497\" title=\"picture 2\">",
"      Mastocytoma infant hand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/34/11813\" title=\"picture 3\">",
"      Sys masto BM stained for ckit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/4784|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/24/38283\" title=\"table 1\">",
"      Tryptase in Ana vs masto",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/20/10572\" title=\"table 2\">",
"      Dx criteria for cutaneous and systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/43/23228\" title=\"table 3\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/15/34044\" title=\"table 4\">",
"      Comparison of mast cell disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/42/12973\" title=\"table 5\">",
"      Diagnostic criteria SM variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15641?source=related_link\">",
"      An overview of angioedema: Clinical features, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/17/34071?source=related_link\">",
"      Idiopathic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/6/34921?source=related_link\">",
"      Mast cell derived mediators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/22/44393?source=related_link\">",
"      Mast cells: Development, identification, and physiologic roles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20936?source=related_link\">",
"      Mast cells: Surface receptors and signal transduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21322?source=related_link\">",
"      Overview of the myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39817?source=related_link\">",
"      Treatment and prognosis of systemic mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=related_link\">",
"      Treatment of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_13_18651="Mechanisms benefit exercise";
var content_f18_13_18651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Biological mechanisms for benefit of exercise",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Antiatherogenic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reduction of adiposity, particularly in those with excess upper body and abdominal fat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reduction of elevated blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Reduction of elevated plasma triglycerides (and associated small dense LDL particles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increase in HDL cholesterol levels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Improvement in insulin sensitivity and glucose use and reduction in risk of type 2 diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antithrombotic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endothelial function alteration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autonomic functional changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-ischemic effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antiarrhythmic effects",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher GF, Balady GJ, Amsterdam EA, et al. Circulation 2001; 104:1694.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18651=[""].join("\n");
var outline_f18_13_18651=null;
var title_f18_13_18652="Concentration of uremic solutes";
var content_f18_13_18652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F85916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F85916&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The concentration of uremic solutes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Molecule",
"       </td>",
"       <td class=\"subtitle1\">",
"        M/N",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &alpha;1-Acid glycoprotein",
"       </td>",
"       <td class=\"centered\">",
"        1.96",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nonanal",
"       </td>",
"       <td class=\"centered\">",
"        1.84",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dihydroxyphenylalanine",
"       </td>",
"       <td class=\"centered\">",
"        1.72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxanthine",
"       </td>",
"       <td class=\"centered\">",
"        1.72",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3-Carboxy-4-methyl-5-propyl-2-furan-propanoic acid",
"       </td>",
"       <td class=\"centered\">",
"        1.70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Soluble intracellular adhesion molecule-1",
"       </td>",
"       <td class=\"centered\">",
"        1.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uric acid",
"       </td>",
"       <td class=\"centered\">",
"        1.59",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cysteine",
"       </td>",
"       <td class=\"centered\">",
"        1.56",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IGF-1",
"       </td>",
"       <td class=\"centered\">",
"        1.52",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adiponectin",
"       </td>",
"       <td class=\"centered\">",
"        1.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-10",
"       </td>",
"       <td class=\"centered\">",
"        1.49",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IL-6",
"       </td>",
"       <td class=\"centered\">",
"        1.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decanal",
"       </td>",
"       <td class=\"centered\">",
"        1.36",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolactin",
"       </td>",
"       <td class=\"centered\">",
"        1.33",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-Hydroxy-2'-deoxyguanosine",
"       </td>",
"       <td class=\"centered\">",
"        1.28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-Octenal",
"       </td>",
"       <td class=\"centered\">",
"        1.25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heptanal",
"       </td>",
"       <td class=\"centered\">",
"        1.20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcitonin",
"       </td>",
"       <td class=\"centered\">",
"        1.09",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Duranton F, Cohen G, Smet RD, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23:1258. Copyright &copy; 2012 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18652=[""].join("\n");
var outline_f18_13_18652=null;
var title_f18_13_18653="Diet and stoma PI";
var content_f18_13_18653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Foods that can affect bowel movements and gas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Foods that make odor worse",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Asparagus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brussel sprouts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cauliflower",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Eggs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fish",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Onions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Some spices",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Foods that increase gas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beer and carbonated soda",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brussel sprouts",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cauliflower",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cabbage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Corn",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cucumbers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mushrooms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Peas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Radishes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinach",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dairy products",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Foods that make bowel movements thicker",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Apple sauce",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bananas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cheese",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boiled milk",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Marshmallows",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pasta",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Creamy peanut butter",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pretzels",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bread",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tapioca",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yogurt",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Foods that make bowel movements looser",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Green beans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Broccoli",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fresh fruits",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Grape juice",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Raw vegetables",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prunes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spicy foods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fried foods",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chocolate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leafy green vegetables",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinach",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18653=[""].join("\n");
var outline_f18_13_18653=null;
var title_f18_13_18654="Graded prognostic assessment for brain metastases by diagnosis";
var content_f18_13_18654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65322&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Graded prognostic assessment for brain metastases by diagnosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Non-small-cell and small-cell lung cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        0.5",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age in years",
"       </td>",
"       <td>",
"        &gt;60",
"       </td>",
"       <td colspan=\"2\">",
"        50-60",
"       </td>",
"       <td colspan=\"2\">",
"        &lt;50",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KPS",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td colspan=\"2\">",
"        70-80",
"       </td>",
"       <td colspan=\"2\">",
"        90-100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extracranial metastases",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td colspan=\"2\">",
"        &mdash;",
"       </td>",
"       <td colspan=\"2\">",
"        Absent",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number&nbsp;of BM",
"       </td>",
"       <td>",
"        &gt;3",
"       </td>",
"       <td colspan=\"2\">",
"        2-3",
"       </td>",
"       <td colspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" class=\"sublist1_start\" colspan=\"6\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Median survival (months) by score: 0-1.0 = 3.0; 1.5-2.0 = 5.5; 2.5-3.0 = 9.4; 3.5-4.0 = 14.8",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Melanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KPS",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td colspan=\"2\">",
"        70-80",
"       </td>",
"       <td colspan=\"2\">",
"        90-100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number&nbsp;of BM",
"       </td>",
"       <td>",
"        &gt;3",
"       </td>",
"       <td colspan=\"2\">",
"        2-3",
"       </td>",
"       <td colspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" class=\"sublist1_start\" colspan=\"6\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Median survival (months) by score: 0-1.0 = 3.4; 1.5-2.0 = 4.7; 2.5-3.0 = 8.8; 3.5-4.0 = 13.2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Breast cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\">",
"        0.5",
"       </td>",
"       <td class=\"subtitle3\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle3\">",
"        1.5",
"       </td>",
"       <td class=\"subtitle3\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KPS",
"       </td>",
"       <td>",
"        &le;50",
"       </td>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        70-80",
"       </td>",
"       <td>",
"        90-100",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subtype*",
"       </td>",
"       <td>",
"        Basal",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        Luminal A",
"       </td>",
"       <td>",
"        HER2",
"       </td>",
"       <td>",
"        Luminal B",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age in years",
"       </td>",
"       <td>",
"        &ge;60",
"       </td>",
"       <td>",
"        &lt;60",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        n/a",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" class=\"sublist1_start\" colspan=\"6\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Median survival (months) by score: 0-1.0 = 3.4; 1.5-2.0 = 7.7; 2.5-3.0 = 15.1; 3.5-4.0 = 25.3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Renal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        1.0",
"       </td>",
"       <td class=\"subtitle3\" colspan=\"2\">",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KPS",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td colspan=\"2\">",
"        70-80",
"       </td>",
"       <td colspan=\"2\">",
"        90-100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number&nbsp;of BM",
"       </td>",
"       <td>",
"        &gt;3",
"       </td>",
"       <td colspan=\"2\">",
"        2-3",
"       </td>",
"       <td colspan=\"2\">",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" class=\"sublist1_start\" colspan=\"6\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Median survival (months) by score: 0-1.0 = 3.3; 1.5-2.0 = 7.3; 2.5-3.0 = 11.3; 3.5-4.0 = 14.8",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist_other\" colspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"7\">",
"        Gastrointestinal cancers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Prognostic factor",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"5\">",
"        Scoring criteria",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Patient score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        0",
"       </td>",
"       <td class=\"subtitle3\">",
"        1",
"       </td>",
"       <td class=\"subtitle3\">",
"        2",
"       </td>",
"       <td class=\"subtitle3\">",
"        3",
"       </td>",
"       <td class=\"subtitle3\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KPS",
"       </td>",
"       <td>",
"        &lt;70",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td align=\"right\" class=\"sublist1_start\" colspan=\"6\">",
"        <strong>",
"         Total:",
"        </strong>",
"       </td>",
"       <td class=\"sublist1_start\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"7\">",
"        Median survival (months) by score: 0-1.0 = 3.1; 2.0 = 4.4; 3.0 = 6.9; 4.0 = 13.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *&nbsp;Basal: triple negative; Luminal A: ER/PR positive, HER2 negative; Luminal B: triple positive; HER2: ER/PR negative, HER2 positive.",
"     <br>",
"      BM: brain metastases; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; KPS: Karnofsky performance score; PR: progesterone receptor.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     From: Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012; 30:419. Reprinted with permission. Copyright &copy; 2012 American Society of Clinical Oncology. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18654=[""].join("\n");
var outline_f18_13_18654=null;
var title_f18_13_18655="Aortic valve bioprosthesis short axis echocardiogram";
var content_f18_13_18655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/67281/shaxbiav_conv.mp4?title=Aortic+valve+bioprosthesis+short+axis+echocardiogram\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bioprosthetic aortic valve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 269px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The short axis view from a 2-D echocardiogram shows a bioprosthetic valve in the aortic position. The sewing ring of the valve can be seen within the aortic root.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_13_18655=[""].join("\n");
var outline_f18_13_18655=null;
               